- 1 {York Stenographic Services, Inc.}
- 2 RPTS KUHNS
- 3 HIF104.180
- 4 H.R. , THE TSCA MODERNIZATION ACT OF 2015
- 5 TUESDAY, APRIL 14, 2015
- 6 House of Representatives,
- 7 Subcommittee on Environment and the Economy
- 8 Committee on Energy and Commerce
- 9 Washington, D.C.

10 The subcommittee met, pursuant to call, at 10:15 a.m.,
11 in Room 2322 of the Rayburn House Office Building, Hon. John
12 Shimkus [Chairman of the Subcommittee] presiding.
13 Members present: Representatives Shimkus, Harper,
14 Latta, McKinley, Johnson, Bucshon, Flores, Hudson, Cramer,
15 Upton (ex officio), Tonko, Schrader, Green, DeGette, Capps,
16 McNerney, Cardenas, and Pallone (ex officio).

17	Staff present: Charlotte Baker, Deputy Communications
18	Director; Leighton Brown, Press Assistant; Noelle Clemente,
19	Press Secretary; Jerry Couri, Senior Environmental Policy
20	Advisor; David McCarthy, Chief Counsel, Environment/Economy;
21	Tim Pataki, Professional Staff Member; Tina Richards,
22	Counsel, Environment; Chris Sarley, Policy Coordinator,
23	Environment and Economy; Jessica Wilkerson, Legislative
24	Clerk; Jacqueline Cohen, Democratic Senior Counsel; Rick
25	Kessler, Democratic Senior Advisor and Staff Director, Energy
26	and Environment; and Ryan Schmit, Democratic EPA Detailee.

Mr. {Shimkus.} The committee will come to order. Before I start with my opening statement, I want to recognize my classmate and my friend, Lois Capps, who has announced her retirement, although I imagine she will be a pain in our side for about a year and a half yet, so a very nice thing. So I will recognize myself for 5 minutes for an opening statement.

T

34 Today marks an important milestone in our effort to modernize TSCA. The more we work together, Member to Member, 35 36 on a bipartisan basis, the more we understand each other and 37 how much we hope to accomplish. Our subcommittee has put in 38 a lot of hours on TSCA over the past couple years, and 39 actually I would say the past couple weeks, and that effort, 40 we believe, is about to pay off. It is gratifying to work 41 directly with Members on both sides of the aisle who bring so 42 much dedication to the task.

A week ago we unveiled the bill before us today.
Besides the bill language itself, that announcement carried a
couple other important messages. First, Members have been
working together directly, challenging each other to find

47 common ground, and discovering that we share many policy 48 objectives. Let's talk about some of those policy 49 objectives. 50 First, I think we all want EPA to do objective, science-51 based examinations on some of the chemicals that are already on the market. EPA already has some of these in mind to 52 53 evaluate because EPA thinks they have potential for 54 unreasonable risk of injury to human health and the environment. Meanwhile, if manufacturers want to take a 55 proactive approach and ask the Agency to perform a risk 56 57 evaluation, we are okay with that as long as it meets the 58 same rigorous science requirements as the ones EPA itself 59 initiates, and the manufacturer is willing to pay the EPA 60 administrative costs of performing the work. 61 We also want to continue protecting confidential

business information, but for CBI claims made after our bill becomes law, we would like manufacturers to reestablish those claims at least once every 10 years. We think EPA should be allowed to mandate testing on a chemical in order to complete a risk evaluation, since the risk evaluation step is new to TSCA.

68 These are just a few of the provisions that appear in 69 the discussion draft. I think we also agree that the process 70 is, and should be, moving forward. Leading Members on both 71 sides are committed to that momentum. We will listen 72 carefully to stakeholders on what they like in the draft, and 73 we welcome suggestions they have for improvement. We will 74 collect those comments and then we will sit down as a 75 subcommittee and make decisions. Members should plan on a 76 subcommittee markup about a month from now on May 14th.

To facilitate our work, we will publish a revised bill text reflecting consensus revisions in time to use as the subcommittee markup vehicle, and I will be asking Chairman Upton to schedule it for full committee consideration as soon as practicable after the subcommittee has done its work.

I thank all of the witnesses today for their willingness to participate. Assistant Administrator Jim Jones, you are no stranger to this committee. Your agency has already offered some informal technical assistance for which we are grateful, and we expect to continue working with you on it until the final version passes both bodies of Congress and is signed by the President.

89	We also welcome our second panel of witnesses. You are
90	all also friends to this Committee and we have been grateful
91	for your perspectives in the past. We look forward to
92	hearing from you on this fresh new approach.
93	Finally, I thank Chairman Upton for his full support on
94	this bill, and my friends, Paul Tonko and Frank Pallone, and
95	the subcommittee members and I would say the subcommittee
96	staff on both sides for all their active participation and
97	partnership in this project. Let's all keep working together
98	to get this vitally important legislation enacted.
99	[The prepared statement of Mr. Shimkus follows:]

101 [The information follows:]

Mr. {Shimkus.} And with that, I yield back my time and yield 5 minutes to the gentleman from New York, Mr. Tonko. Mr. {Tonko.} Thank you, Mr. Chair, and I certainly appreciate the tone. I value the friendship and partnership we have in serving this committee.

108 Good morning to each and every one of our witnesses and 109 to my fellow panelists here. Thank you, Chair Shimkus, for 110 calling this important hearing, this very important hearing.

111 Our subcommittee spent a good deal of time on the Toxic Substances Control Act in the last Congress. We had a number 112 113 of very good hearings covering many of the provisions of the 114 current law, and although we did not get to an agreement, the exercise provided the members of this subcommittee with a 115 much better understanding of the current law and its 116 117 associated shortcomings. It is a new Congress. We have 118 another opportunity to develop a bill to address the key problems with current law. 119

For much of the past 37 years, TSCA served the industry well, but I would caution that TSCA needs to be balanced. It needs to serve all perspectives well. Existing chemicals

123 remain on the market, and new chemicals entered commerce 124 through a limited review process that does not require 125 licensing or compel the production of minimal data sets. 126 Information provided by chemical manufacturers could be labeled as confidential business information with less review 127 128 of whether the CBI claims were justified or not. Even in the 129 face of strong evidence that a chemical substance indeed 130 presented a significant risk, the Environmental Protection 131 Agency was unable to act.

132 For all practical purposes, TSCA has no enforceable safety standard. Under the law's standard of unreasonable 133 134 risk and the requirement to produce substantial evidence, the 135 burden of proof of harm as interpreted by the courts is too high to enable EPA to address even well-characterized risks. 136 137 In addition, the Agency has insufficient resources and little 138 authority to require manufacturers to produce information for 139 an adequate evaluation of those chemical risks. This is 140 especially true for thousands of older chemicals that 141 remained in commerce with no evaluation from the time the law 142 was passed to the present moment.

143 The overriding problem with TSCA is that the public has

144 no confidence in this federal program. As a result, the 145 public does not believe that the presence of a chemical in 146 the marketplace has any relationship to its safety. That is 147 not good for industry and it is not good for the public. The 148 federal program must have credibility.

149 The discussion draft that is the subject of today's 150 hearing represents a significant departure from the proposal 151 offered by Senator Vitter and Senator Udall, and I believe 152 that is an important step here in this House. It is also 153 different from the approach taken in the House last year. So I believe that this draft has a number of benefits relative 154 155 to these two other proposals, and that is a very beneficial 156 thing in this process.

I want to commend the chair for working with us and demonstrating a desire to discuss and address concerns raised by Democratic members and by different stakeholders and interest groups. I appreciate and applaud the Chair's decision to narrow the scope of this effort and to focus on the key problems with TSCA.

163 Again, I appreciate the partnership and the friendship,164 but there is much more work to do, and I am prepared to work

165 with you as are the other members of our subcommittee, Mr. Chair. My hope is that we can produce a bill that all 166 167 members of our subcommittee can support, one that truly can 168 become law. If we are to do that, the final product must reflect compromise and gain the support of a broad coalition 169 170 representing all of the major stakeholder groups and it must 171 have the support of the Administration. I believe we can get 172 there and that this discussion draft makes a great start 173 toward the goal of passing a law but I do not want to mislead 174 anyone. There are still some tough issues to address. A new TSCA must do more for public health and the environment than 175 176 the current law. It must preserve state authority to act to 177 protect their citizens in the absence of meaningful federal action, and changes in policy alone will not be enough. 178 The 179 Agency must have adequate resources by which to fulfill its 180 obligation to the public and to the regulated community. A 181 reformed TSCA should generate more innovation, not more 182 litigation.

183 I want to thank all of our witnesses who are 184 participating in today's very important hearing. Your input 185 on this draft legislation will be very important to our

186	efforts as we move forward, and again, I would like to thank
187	you, Mr. Chair, and commend you for tackling this important
188	and very challenging issue. It is not easy. I look forward
189	to working with you and the other members of this
190	subcommittee to complete this very important task.
191	And with that, I yield back.
192	[The prepared statement of Mr. Tonko follows:]

Mr. {Shimkus.} The gentleman yields back his time, and you know, without objection, what I would like to do, Mr. Jones, is allow you to go for 5 minutes, and then when Chairman Upton and the ranking member come, after that we will let them give their opening statements, and with that, you are recognized for 5 minutes. Welcome.

201 ^STATEMENT OF HON. JAMES JONES, ASSISTANT ADMINISTRATOR,
202 OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION, U.S.
203 ENVIRONMENTAL PROTECTION AGENCY

204 } Mr. {Jones.} Thank you. Good morning, Chairman 205 Shimkus, Ranking Member Tonko, and other members of the 206 subcommittee. I appreciate the opportunity to join you today 207 to discuss the much-needed reform of chemicals management in 208 the United States and the opportunity to engage early on the 209 recently released discussion draft, the TSCA Modernization 210 Act of 2015.

As you know, chemicals are found in almost everything we buy and use. They contribute to our health, our well-being and our prosperity. However, we believe it is essential that chemicals are also safe.

TSCA gives the EPA the jurisdiction over chemicals produced, used, and imported into the United States. However, unlike laws applicable to pesticides and drugs, TSCA does not have a mandatory program that requires EPA to conduct a review to determine the safety of existing

220 chemicals. In addition, TSCA places burdensome legal and procedural requirement on the EPA before the Agency can 221 222 request a generation and submission of health and 223 environmental effects data on existing chemicals. As a result, in the more than 3-1/2 decades since the passage of 224 225 TSCA, the EPA has only been able to require testing on a 226 little more than 200 of the original 60,000 chemicals listed 227 on the TSCA inventory and has regulated or banned only five 228 of these chemicals under TSCA Section 630, the last of which 229 was in 1990. In the 25 years since, the EPA has largely relied on voluntary action to collect data and address risks. 230 231 In the absence of additional federal action, an 232 increasing number of States are taking actions on chemicals to protect their residents, and the private sector is making 233 234 their own decisions about chemicals to protect their interest and to respond to consumers, it is clear that even with the 235 236 best efforts under current law and resources, we need to 237 update and strengthen TSCA and provide the EPA with the 238 appropriate tools to protect the American people from exposure to harmful chemicals. 239

240 The EPA believes that it is critical that any update to

241 TSCA include certain components. In September 2009, the Administration announced a set of six principles to update 242 243 and strengthen TSCA. 244 While the Administration does not have a position on the 245 discussion draft, there are several important observations 246 that I would like to offer. 247 The discussion draft provides the EPA with more 248 effective authority to compel the generation of health and 249 safety data on existing chemicals. The discussion draft 250 should give the EPA authority to set priorities for conducting safety reviews on existing chemicals based on 251 252 relevant risk and exposure considerations. The draft 253 includes two means by which risk evaluations could be initiated for existing chemicals. The first is that EPA 254 255 would be required to conduct a risk evaluation upon a finding 256 that the combination of hazard from and exposure to a 257 particular chemical substance has the potential to create an 258 unreasonable risk of injury to health or the environment. 259 The second allows for a chemical manufacturer to request that EPA conduct a risk evaluation for a particular chemical 260 261 substance. In practice, this would likely lead to EPA

262 focusing the majority of its limited risk evaluation resources on completing evaluations for chemical substances 263 264 requested by industry, which, once requested, start the clock 265 ticking on a number of deadlines. This could result in evaluations for the chemicals with the most potential for 266 267 risk being put off indefinitely while EPA works on the 268 evaluations requested by industry. Additionally, the 269 requirement that EPA make an affirmative finding of the 270 potential for unreasonable risk, prior to initiating a risk 271 evaluation, creates a possible analytical catch-22 in which EPA must make a finding regarding the potential for risk 272 273 prior to beginning the risk evaluation process. I note that 274 once the EPA is able to conduct an evaluation that finds risk, the discussion draft appears to impose rigorous 275 276 deadlines for taking regulatory action to reduce those risks. 277 However, in many cases the deadlines in the draft are 278 unreasonably short.

The use of TSCA section 6 to limit or ban a chemical that poses a significant risk has been a major challenge. The discussion draft clearly removes TSCA's requirement that the EPA demonstrate it is using the least burdensome

283 requirements needed to provide adequate protection. The draft appears consistent with Principle 1 in that it 284 285 specifies that risk assessments should include consideration 286 of information on potentially exposed populations but not 287 information on cost and other factors not directly related to 288 health or the environment. The discussion draft, however, is 289 ambiguous on how EPA is to incorporate cost and other factors 290 into a risk management rule under section 6(a). 291 In the current discussion draft, the cap on fees is eliminated; however, there are not provisions that ensure EPA 292 293 will be given a sustained source of funding for 294 implementation, as articulated in Principle 6. The 295 discussion draft is consistent with the Administration 296 principles in the area of transparency and availability of information on chemicals, including giving the EPA the 297 298 ability to share chemical data with state, local and tribal 299 governments. 300 Mr. Chairman, thank you again for your leadership on

301 TSCA reform. I will be happy to answer any questions you or 302 other members have.

303 [The prepared statement of Mr. Jones follows:]

Mr. {Shimkus.} Thank you very much for your opening statement, and I appreciate the comments I would like to turn to Chairman Upton and thank him for his friendship and support as we move forward, and you're recognized for 5 minutes.

310 The {Chairman.} Well, thank you, Mr. Chairman.

311 It is today an important milestone as we work to bring 312 our chemical safety laws into the 21st century, and I thank 313 Chairman Shimkus for his bipartisan member-to-member work 314 bringing this legislation before the subcommittee. I also 315 commend the ranking member of the full committee, Mr. 316 Pallone, for collaborating across the aisle to develop a 317 proposal that in fact we can all embrace.

318 We have heard from a diverse cross-section of 319 stakeholders that TSCA needs modernizing. When first enacted 320 nearly four decades ago, the structure was a bit of an 321 experiment. When our predecessors on this committee designed 322 TSCA, they were clearly attempting to reconcile diverse 323 points of view within Congress and with the American public. 324 But our challenge today is the same, but now we have the

325 benefit of experience. Our witnesses include the Administration's main point person on chemical regulation, 326 327 industry experts with global regulatory experience, and a person who manages a chemical business on a day-to-day basis. 328 329 As someone responsible for meeting the payroll, she may have 330 the most valuable experience of all. We look forward to all 331 of your testimony today as we collectively work together in 332 the days ahead to get the project done.

Last year we spent lots of hours, countless hours, trying to develop bipartisan legislation only to find that we put more issues on the table than we could resolve. Drawing on that lesson, this year's bill is a little bit more focused.

338 First, it kicks the starting process of selecting 339 chemicals already in commerce for risk evaluation and, if necessary, rulemaking to mitigate that risk. From among 340 341 chemicals already on the market, EPA selects ones that it 342 sees as potentially posing an unreasonable risk. Second, the 343 bill also lets the market select chemicals for risk 344 evaluation by allowing a manufacturer to ask for and pay for 345 an evaluation. In either case, the risk evaluation must

346 stand up to rigorous scientific standards set out in the legislation. If EPA does identify an unreasonable risk, it 347 348 must turn immediately to drafting a rule tailored to mitigate 349 that risk. These rules will focus on the danger at hand. 350 Once written, those rules will be shared by all Americans. 351 Rooted in science, the EPA decisions will obviate state-by-352 state attempts to regulate interstate markets, and everyone 353 from moms in Michigan to consumers around the world will have 354 the confidence that a chemical cleared by EPA won't harm them 355 or their families. So let's continue the bipartisan momentum 356 and get this legislation through the committee and the full 357 House. This is the year for meaningful reform. 358 I again want to particularly thank Mr. Shimkus for his

359 strong work to get a bill to the plate where we can finally 360 get some runs scored. Yield back.

361 [The prepared statement of Mr. Upton follows:]

Ι

363 Mr. {Shimkus.} The gentleman yields back his time. The 364 chair now recognizes the ranking member of the full 365 committee, Mr. Pallone, for 5 minutes.

366 Mr. {Pallone.} Thank you, Mr. Chairman.

367 I am pleased to be here today to continue this 368 subcommittee's important work to reform the Toxic Substances 369 Control Act. Chairman Shimkus's new discussion draft, the 370 TSCA Modernization Act of 2015, is a thoughtful and 371 innovative approach that has the potential to move chemical regulation forward. The chairman and the Majority staff have 372 373 worked closely with Democratic members, including our ranking 374 member, Mr. Tonko, to improve this draft, and I am happy to say that our work is ongoing. I look forward to hearing from 375 EPA, affected industries, and environmental stakeholders this 376 377 morning to plot a course forward and begin to strengthen this 378 draft.

379 Improving the federal government's ability to identify 380 and manage risks from the chemicals that are manufactured and 381 processed in this country is critical. For 6 years now, 382 there has been widespread agreement among industry, labor,

383 and nongovernmental organizations that TSCA needs to be 384 reformed. 385 In 2009, the EPA Administrator said that TSCA had proven to be ``an inadequate tool for providing the protection 386 against chemical risks that the public rightfully expects.'' 387 388 The American Chemical--or I should say, the American 389 Chemistry Council said it wanted to work with stakeholders, 390 Congress, and the Administration to make reform a reality. 391 And a coalition of public interest groups said that by 392 updating TSCA, Congress can create the foundation for a sound and comprehensive chemicals policy that protects public 393 394 health and the environment while restoring the luster of 395 safety to U.S. goods in the world market. 396 At that time, stakeholders and policymakers pursued a 397 vision of a fully reformed TSCA, ensuring that no chemical 398 would go on the market without being found to be safe. All 399 chemicals in commerce would be subject to minimum testing, 400 and aggressive regulation would ensure to the American public 401 a reasonable certainty of no harm from the chemicals they are 402 unwittingly exposed to every day. Six years later, that 403 vision is still my goal but the risks from toxic chemicals in

404 our environment and the products we use every day are serious and pressing, and progress toward that vision has been 405 406 elusive. 407 This new discussion draft does not attempt to realize 408 the goal of a fully reformed TSCA with assurances that all 409 chemicals in commerce are safe but it will give EPA tools to 410 reduce risk now, in a package that I think has the potential 411 to become law, and it will give consumers the ability to 412 choose chemicals and products that have been reviewed for

413 safety against a purely risk-based standard.

414 Under this draft, EPA would have the ability to require 415 testing through orders, rather than just rulemaking. That is 416 an important step forward, although it won't fix all of the problems in Section 4 of the existing law. The draft would 417 418 also ensure that EPA's determinations of unreasonable risk under section 6 of current law will be made without 419 420 consideration of costs and with explicit protections for 421 vulnerable populations. EPA would then be able to move 422 forward with risk management without the paralyzing requirement to select the least burdensome option. These too 423 are essential steps forward, although issues in section 6 424

425 still remain.

Additionally, the draft would remove outdated limits on 426 427 user fees to provide more resources for EPA's activities under TSCA, although it could do more to ensure that EPA 428 actually receives those funds. The draft also would direct 429 430 EPA to update the TSCA inventory, providing better 431 information to consumers and policymakers on the universe of 432 chemicals in commerce in the United States, and the draft 433 would require substantiation of CBI claims in the future, 434 preventing abuse of CBI claims and ensuring greater transparency. These are all positive changes that would 435 436 empower EPA to offer greater protections for human health and 437 the environment. Importantly, the draft also avoids some of 438 the significant concerns that have been raised about past 439 proposals, such as limits on the ability of EPA to regulate 440 articles and limits on the ability of states to be partners 441 in enforcement.

This bill reflects robust bipartisan outreach, which I hope to continue in the coming weeks. Mr. Chairman, you deserve credit for a strong process so far, and a strong product. Some important issues remain to be worked out, such

446 as setting yearly targets for EPA initiated risk evaluations, 447 ensuring that private rights of action are protected, and 448 targeting risks from the worst of the worst chemicals, PBTs. 449 So I hope we can come together to strengthen this proposal 450 and produce a law. 451 I welcome the testimony from today's witnesses, which 452 will point the way for further work on a bipartisan basis. 453 We have all, Mr. Shimkus, myself, Mr. Tonko and of course Mr. 454 Upton, we really consider this a goal that can be 455 accomplished on a bipartisan basis, and I just want to thank everyone for all their hard work, particularly over the last 456 457 2 weeks. You know, we had a recess for 2 weeks but the staff were certainly not in recess. They were working very hard on 458

459 this bill.

460 Thank you, Mr. Chairman.

461 [The prepared statement of Mr. Pallone follows:]

Mr. {Shimkus.} Thank you. I also want to thank you for your personal involvement, and we were working. There was a conference call for about an hour, and I think you were on the road somewhere and I was on the road somewhere, and staff was here, and it was a good start, so people were working hard, and I appreciate it.

469 Now I would like to recognize 5 minutes to start the 470 questions, and Mr. Jones, how many chemicals already on the 471 market is EPA currently assessing on a yearly basis? And I 472 think check the microphone.

473 Mr. {Jones.} I am sorry.

474 Mr. {Shimkus.} That is all right.

Mr. {Jones.} Thank you. We identified about 80 475 476 chemicals several years ago for assessment. We have assessed final assessments for five of them, and we have about 20 477 under evaluation right now, so it is hard, since we are so 478 479 early in the early days of attempting to evaluate existing 480 chemicals, it is hard to right now estimate exactly how many 481 per year we are doing. Somewhere in the range between three 482 and eight I would say would be an accurate number.

483 Mr. {Shimkus.} To evaluate, let's say, 20 chemicals per 484 year, how much many and staff would you need? Do you have--485 Mr. {Jones.} I would think we would need at least twice 486 the existing chemical resources we have right now to do 20 a 487 year.

488 Mr. {Shimkus.} Would the discussion draft, particularly 489 the section--you kind of highlighted part of this in your 490 testimony--requiring manufacturers to pay all costs related 491 to the requested reviews all you, the EPA, to have more 492 chemicals evaluated?

Mr. {Jones.} Yeah. One of the tricks that we have 493 494 observed in the way the bill is drafted is that those 495 resources actually don't come to EPA, and so they go to the 496 Treasury, and so we are limited by the appropriated resources 497 that we have, so it doesn't really expand our capacity. 498 Mr. {Shimkus.} Yeah. Is there--and that is why we have 499 the hearing and stuff because--I am being whispered in my ear 500 that you are right, so we obviously--the intent is for--if 501 there are user fees, the whole intent is for you to be able 502 to get access to it so you can have the ability. And so if there are ways that you get your smart people involved and we 503

504 get our smart people involved, maybe there is--I don't know what we can do but we need to make sure that that happens. I 505 506 think that is the intent--what is that, Mr. Chairman? I know 507 I am not the smart quy. Does the discussion draft improve the agency's ability 508 509 to require the submission of hazard and exposure data by 510 authorizing the EPA to obtain it by rule, consent agreement, 511 or by issuing an order? 512 Mr. {Jones.} Yes, it does. 513 Mr. {Shimkus.} Does the discussion draft allow EPA to 514 select and do risk evaluations on chemicals whose exposures 515 and hazards have the potential to be high enough to create an 516 unreasonable risk? Mr. {Jones.} Well, it is interesting because the 517 518 language creates an additional step that we don't have today 519 and that we have to--that is why I refer to it as the 520 potential catch-22. We actually have to make a finding

521 before we can initiate a review, and that finding is somewhat 522 related to risk, even though the whole point of a risk

523 evaluation is to determine the risk. So it creates somewhat

524 of a barrier actually to initiating a risk evaluation.

525 Mr. {Shimkus.} And obviously the intent of the legislation is to be, as was stated in some of the opening 526 527 statements, a more slimmed-down, more efficient, more simplistic process of getting from A to B to C to judgment 528 529 ruling, so we want to make sure we have that, and any help 530 you can provide in addressing that, we would be--because look 531 at schematics of current law, and you look at schematics of 532 other possible laws, they are much more complex, and we would 533 like to--our intent is not to be--our intent is just to get 534 the job done.

535 Mr. {Jones.} I think that could be achieved.
536 Mr. {Shimkus.} The discussion draft excludes cost
537 considerations when EPA performs risk evaluations, saving
538 that issue for when and if a risk management rule is written.
539 Do you agree that the risk evaluation should focus on hazard
540 and exposure?

541 Mr. {Jones.} Yes.

542 Mr. {Shimkus.} You testified that the discussion draft 543 is ambiguous on how EPA is to incorporate cost and other 544 factors into a risk management rule under section 6A. Can 545 you explain why you said that?

546 Mr. {Jones.} Thank you. That is probably one of the most important observations that we have around the 547 548 discussion draft. So the existing standard of unreasonable 549 risk has been interpreted by courts to be a risk-benefit balancing where the Agency has actually got to demonstrate 550 551 that the health benefits of the rule literally outweigh the 552 costs imposed by the rule. It is not clear whether or not 553 that interpretation that exists right now would be changed at 554 There are some parts of the draft that make it appear all. 555 that actually cost shouldn't come into consideration in determining the level of protection achieved, but that would 556 557 conflict with the cost-benefit balancing that previous courts 558 have determined, and then there is the cost-effectiveness language, and so our observation is, it is not clear if this 559 560 discussion draft is maintaining the existing cost-benefit 561 balancing, if it is attempting to exclude costs completely from the risk management, or if it wants costs considered but 562 563 in some general way without being explicit. So it is a 564 clarity issue from our perspective.

565 Mr. {Shimkus.} Thank you, and my time is expired, but I 566 think you have raised an issue that what is the--you have

- 567 courts--decisions courts have rendered and then
- 568 simplistically changing a law, so my guess is, the courts

569 would then have to render judgment under new statutes versus

- 570 old statutes.
- 571 So having said that, I will recognize the ranking 572 member, Mr. Tonko, for 5 minutes.

573 Mr. {Tonko.} Thank you, Mr. Chair, and again, much 574 exchange here has cited the hard work done over the last 575 couple of weeks, so allow me to further compliment and thank 576 the staff for their devotion to this effort along with my 577 colleagues.

We need TSCA reform certainly because under current law, the American public is exposed to industrial chemicals without that sufficient bit of safeguard to protect public health. So tens of thousands of chemicals in commerce have never been tested for safety, and EPA does not currently have the necessary authority or resources to tackle this backlog. So Mr. Jones, what is EPA currently doing to address the

585 highest-priority chemicals under TSCA?

586 Mr. {Jones.} Thank you, Congressman Tonko. So we 587 identified--we evaluated the 1,200 or so chemicals with known

588 hazard, and we compared them against criteria that were related to severity of hazard as well as the potential for 589 590 exposure, and from that priority-setting process, we have identified a little over 80 chemicals that we think are the 591 592 most important to assess first, and we have now begun to 593 assess those chemicals. 594 Mr. {Tonko.} And then would this draft as it currently 595 stands enable that work plan? 596 Mr. {Jones.} It sets a little bit of a higher bar than the priority process that we did in making a judgment that 597 there is actually the potential for the exposure to exceed 598 599 the hazard, which we did not do in our priority--600 Mr. {Tonko.} Any clarification that we need to have in 601 the language that we are proposing? 602 Mr. {Jones.} I think we don't want to create a potential unmanageable bar, I think if that might be useful. 603 604 Mr. {Tonko.} Okay. The last thing we should do in TSCA 605 legislation is make it harder for EPA to act against the 606 worst chemicals. What changes could we make to ensure that 607 the chemicals EPA thinks are the highest priority get reviewed and addressed? 608

609 Mr. {Jones.} Well, as I mentioned, having a requirement that we make a finding that the exposure may exceed the risk 610 611 before we have actually done the risk assessment is I think 612 an unnecessary requirement up front. And then as I mentioned earlier, I think it is important that we all have a clear 613 614 understanding of what the actual risk management standard is, 615 and I don't think it is clear right now what that standard 616 is, which opens the potential for there to be a lot of 617 litigation after decisions are made.

618 Mr. {Tonko.} And adding a minimum number for EPA is a
619 beneficial thing when it comes to initiating reviews?
620 Mr. {Jones.} If the Congress wants a certain pace to b

620 Mr. {Jones.} If the Congress wants a certain pace to be 621 achieved, and my experience is that being clear about what 622 kind of--what your expectations are about how quickly the 623 Agency acts is pretty important.

Mr. {Tonko.} Let me focus on the role of cost considerations that the chair was quizzing you about, and using those costs in the effort to assess and manage risks. This bill includes, as he indicated, explicit language to indicate EPA's risk evaluation cannot take cost into consideration. The language is intended to ensure that EPA's

630 determination of whether or not a chemical presents an unreasonable risk does not include cost considerations but 631 632 cost analyses are never part of that risk. They are, however, or should be included in an analysis of the options 633 available to reduce identified risks for risk management. So 634 635 are there--and again, I heard the give and take, the 636 bantering that you and the chair had, but are there suggested 637 changes that you can share that would make that effort more 638 clear?

Mr. {Jones.} Yeah, I think that the--and this goes back 639 to the risk management standard Congress is trying to put 640 641 into place, and the Administration believes the costs are an 642 important consideration in risk management, which is 643 different from saying that the risk management standard 644 should be a risk-benefit balancing, as I have testified 645 before. In the chemicals arena, that is a very challenging 646 thing to do because the risks that we are looking at are 647 often not quantifiable but the costs almost always are, and 648 what we got out of the Corrosion Proof case was a finding 649 that the Agency had to numerically determine that those 650 benefits literally numerically were larger than the costs,

651 which creates--you end up with a cost-biased standard, which has been one of the problems that we have had. So being 652 653 clear about whether the Congress is looking for a costbenefit balancing or you want a standard that requires the 654 consideration of costs, which may not sound like it is a lot 655 656 different but actually in reality it is quite different, 657 would be very useful. 658 Mr. {Tonko.} Well, I think any kind of, you know, 659 suggested changes would be very helpful for the subcommittee

660 as we move forward, and I appreciate your input here today.

661 I yield back.

662 Mr. {Shimkus.} The gentleman yields back his time. The 663 chair now recognizes the vice chair, Mr. Harper, for 5 664 minutes.

Mr. {Harper.} Thank you, Mr. Chairman. Mr. Jones, thank you for being here today and shedding some light on a very important subject for us, and we look forward to working together on both sides of the aisle and with you on coming up with a solution that works, and I appreciate your input on the discussion draft today.

671 You testified that priority chemicals should be assessed

672 and acted upon in a timely manner if the chemical poses a risk. For your work plan chemicals, have you determined that 673 674 some show an unreasonable risk? 675 Mr. {Jones.} So we have demonstrated with the five 676 assessments we have completed that three of them demonstrate 677 risk. Two of them we said were not significant risks. But 678 unreasonable risk under current TSCA has been interpreted by 679 courts to mean that the health benefits outweigh the costs, 680 and so what we are doing right now for the three chemicals 681 where we have demonstrated significant risks were evaluating the health benefits that we have identified and comparing 682 683 them to the cost of potential regulation and ultimately we need to come up with a risk management that balances the 684 health benefits with the costs. So that is the part of the 685 686 process that we are in right now. 687 Mr. {Harper.} So the three of the five that you are

688 moving forward on, you haven't completed that process, 689 correct?

Mr. {Jones.} That is correct. We are in that process.
Mr. {Harper.} So what is the status of the risk
management rules on those particular three chemicals?

Mr. {Jones.} So we are right now--we have articulated the health benefits, the risk, and we are right now evaluating the cost of potential regulation, which also involves looking at evaluating the risks and the benefits of the alternatives and determining whether or not we have figured out the least burdensome way to adequately protect against the risk.

Mr. {Harper.} You know, when you have those five that you were looking at, ruling two of those, did you start the process on all five at the same time?

703 Mr. {Jones.} Yes, we did.

Mr. {Harper.} And are they supposed to proceed at the same pace, or I assume each one can be at a different level, but are you proceeding--are the three that you are looking at, are they at the same spot in the process?

Mr. {Jones.} They are actually, although that is a little bit by happenstance because sometimes you run into a difficult issue and it may take a little longer to resolve, but the three that we are looking at, whether or not there is unreasonable risk, they are moving at pretty much the same pace.

714 Mr. {Harper.} Now, you said there are 80 that have been 715 identified. 716 Mr. {Jones.} That is correct. 717 Mr. {Harper.} And how many--who determines which ones are looked at next and assessed? 718 719 Mr. {Jones.} That would be me. 720 Mr. {Harper.} Okay. 721 Mr. {Jones.} We actually had a public process where we 722 identified factors that we wanted to look at. They were 723 factors like carcinogenicity, reproductive toxicity, persistence bioaccumulation, and we also wanted to make sure 724 725 there was exposure so that we weren't looking at potentially 726 hazardous chemicals for which nobody was being exposed. We 727 had public participation around that at some workshops, and 728 then we finalized the criteria, and then we evaluated about 729 1,200 chemicals against the criteria that we developed, and 730 these are the ones that came out on top. 731 Mr. {Harper.} So how many assessments do you believe 732 will be completed this calendar year? 733 Mr. {Jones.} That is a tricky one because we are taking on some--there are at least three that will be above the five 734

735 that we have done that is very clear will be completed. We are also looking at some of the most challenging compounds, 736 737 which are flame retardants, and we are looking at several 738 dozen of those, and they are quite complicated, so it is hard for me at this point to predict how many of the flame-739 740 retardant assessments we will complete. 741 Mr. {Harper.} Yield back the balance of my time. 742 Mr. {Shimkus.} The gentleman yields back his time. The 743 chair now recognizes the ranking member of the full 744 committee, Mr. Pallone, for 5 minutes. 745 Mr. {Pallone.} Thank you, Mr. Chairman. 746 The testimony we hear today will be essential as we work 747 to move this draft forward, and I know we have heard already 748 today and we will continue to hear from the second panel that 749 there are a number of changes needed to the draft, and I 750 appreciate my colleague, Mr. Tonko, for highlighting some of 751 those changes. I would like to focus briefly on some of the 752 things I think this draft gets right, and if you can to just 753 answer yes or no, but I am not going to restrict you 754 completely. I just want to get through it. 755 First, I would like to highlight some of the problems in

756 current law that I think this draft addresses. So Mr. Jones, 757 does this draft remove the least-burdensome language that has 758 been an obstacle to EPA action under section 6? 759 Mr. {Jones.} Yes. 760 Mr. {Pallone.} Does the draft remove the statutory cap 761 on user fees in existing law? 762 Mr. {Jones.} Yes. 763 Mr. {Pallone.} Is it your view that the draft needs to 764 do more to ensure that EPA actually receives adequate 765 resources to carry out this program? Mr. {Jones.} Yes, and I would just say it is because 766 the draft as written right now does not allow the fees to 767 768 come to EPA. 769 Mr. {Pallone.} Okay. Would you have any recommendation 770 in that regard? 771 Mr. {Jones.} We could work with the committee to figure out how to write that. We have done this before. 772 773 Mr. {Pallone.} Okay. Well, I just hope that we can 774 make changes to ensure that EPA has the resources as we move 775 forward. Otherwise, you know, what goes is it? 776 Turning back to the draft, does this draft require

777 justification of future CBI claims, unlike current law? 778 Mr. {Jones.} Yes. 779 Mr. {Pallone.} And does this draft provide explicit protections to vulnerable populations and therefore improve 780 781 current law? 782 Mr. {Jones.} It is a little ambiguous. It precludes 783 EPA from determining a chemical meets the safety standard 784 unless we have evaluated vulnerable populations but doesn't 785 speak to scenarios where we find that the safety standard is 786 not met. 787 Mr. {Pallone.} Okay. I think these are all very 788 important points, and I recognize that the draft is not as 789 comprehensive as some past proposals, but I think it would 790 move the ball forward on chemical regulation and improve 791 current law. 792 I also wanted to recognize again the subcommittee 793 chairman, Mr. Shimkus, because he has tried to avoid some of

794 the major issues that have stalled proposals in the Senate.

795 So let me ask you about some of that.

796 Mr. Jones, I know that you raised concerns about article 797 provisions in the Senate bill. Are those concerns addressed

798 here?

799 Mr. {Jones.} Yes, they are.

800 Mr. {Pallone.} Okay. And you also raised some concerns 801 about the ability of states to co-enforce requirements of EPA 802 TSCA rules and to regulate chemicals while EPA is evaluating 803 them. Are those concerns addressed here?

804 Mr. {Jones.} Yes.

Mr. {Pallone.} Okay. I think it is--again, I think this draft is a good starting point. Obviously we still have a lot of work to do but we have had a very good process so far, and I look forward to continuing to work with the chairman and Mr. Tonko. And so at this point, I can't believe I am actually yielding back, but I accomplished everything I wanted to accomplish.

812 Mr. {Jones.} It was my short answers.

813 Mr. {Pallone.} Thank you.

814 Mr. {Shimkus.} The gentleman yields back his time, and 815 I hope those answers are helpful to you and I hope they are 816 not harmful to me.

817 So with that, I would like to yield 5 minutes to the 818 gentleman from Ohio, Mr. Latta, for 5 minutes.

819 Mr. {Latta.} Well, thank you very much, Mr. Chairman, and thanks very much for holding this very important hearing 820 821 today, and Administrator, thanks for being with us today. 822 Last year when you testified before the subcommittee, in 823 April, in fact, just about a year ago, I discussed with you 824 the TSCA inventory. You stated how the actual number of 825 chemicals on the TSCA inventory somewhere between 7,000 and 826 84,000, the 7,000 number being the rough number of chemicals 827 produced in large quantities and overall the 84,000 representing those chemicals that have been on the inventory 828 829 and how it could be potentially misleading. Let me ask, do 830 you believe that the discussion draft before us would give a 831 more accurate picture of the chemicals actually in commerce on any given date? 832 833 Mr. {Jones.} It would, yes. 834 Mr. {Latta.} Okay. And also, how effective do you 835 believe the least-burdensome provision has been under the 836 current law? 837 Mr. {Jones.} I think it has created a barrier under the 838 current law.

839 Mr. {Latta.} Okay. Could you explain that, how it has

840 created a barrier?

841 Mr. {Jones.} So for example, right now there are three 842 chemicals that we have identified as posing significant risk, and before we can move forward regulating them, we have to 843 844 evaluate about eight different risk management scenarios that 845 are identified in the statute and show how for each one of 846 them we are selecting the one that poses the least burden on 847 society at large, so we have to analyze each of these 848 potential risk management options and then just pick the 849 least burdensome one, which as a general matter I don't have 850 a problem with but it is not always necessary to evaluate 851 everything to know which one is going to be the least 852 burdensome ultimately and we are required to do that under 853 the statute.

854 Mr. {Latta.} Let me ask, how much time does that add to 855 the process?

Mr. {Jones.} Well, you know, we are doing it right now for the first time in 30 years, and so I will have a clearer answer when we have actually finished that analysis, and whether or not a court ultimately upholds did we do enough analysis for each of the risk management options that are in

861 the statute.

880

Mr. {Latta.} Let me ask about under the proposed draft 862 863 bill before us is on the deadlines, and you know, the deadlines we are looking at that the Administration will 864 865 conduct and publish risk evaluation under the subsection for 866 chemical substance not later than 3 years after the date on 867 the Administrator makes a finding, 180 days after the date on 868 which the manufacturer requests the risk evaluation, and it 869 also goes on to state that if the Administrator determines 870 that additional information is necessary to make a risk evaluation, a determination under the subsection, there is--871 872 it can be extended a date of 90 days after receipt of 873 additional information or 2 years after the original deadline, and with that, you know, where do you see that -- do 874 875 you see that would be a good time frame? 876 Mr. {Jones.} You know, I think deadlines are really 877 important for the government to have, but they are pretty 878 short, and the only one that I think that the Agency has some 879 potential for meeting is the initial assessment if EPA

881 between 2 and 3 years, so having the deadline be the latter

47

initiates the review, 3 years-our experience so far is that

882 end of it seems appropriate.

Us turning an assessment around in 6 months from an industry submission I think is unrealistically optimistic. I would love to be able to do proposed rules within 6 months of a safety evaluation. My experience is that that is also just unrealistic from past experience.

Mr. {Latta.} Well, you know, with the 3 years, you know, how long on general--you are saying 2 to 3 but how many different chemicals are out there that have taken more than 3 years for you to do an evaluation on?

Mr. {Jones.} So it is possible that something that is hugely challenging from an exposure potential or hugely challenging from understanding the hazard that it would take longer than 3 years, I would expect that as a general matter, 3 years is a deadline that could be achieved for the vast majority of the chemicals we would evaluate.

898 Mr. {Latta.} Well, thank you very much, and--

899 Mr. {Shimkus.} Will the gentleman yield the last 44
900 seconds?

901 Mr. {Latta.} I yield back.

902 Mr. {Shimkus.} Under the industry applied evaluation,

903 you will have more data in that process than when you just 904 pick a chemical out of the air and say we have to do this one 905 as our requirement under current law. Is that correct? 906 Mr. {Jones.} It is not clear that that would be the 907 case. I assume that that was some of the assumptions that 908 were built into that 6-month deadline. It is not obvious the 909 way it is drafted that we would have more. The other--910 Mr. {Shimkus.} Well, if the industry is willing to have 911 you expedite this, my guess is that there would be, you know, 912 a working relationship that -- but we will work to clear that 913 up. My assumption would be, they are going to give you what 914 they have to try to get an expedited--I mean, that is the 915 whole benefit of going through this process is coming to a 916 decision.

917 Mr. {Jones.} Yeah. The draft is written that all they 918 have to do is request it, so they don't have to actually give 919 us anything.

920 Mr. {Shimkus.} Okay. Thank you. I thank my colleague.921 The chair now recognizes the gentleman from Oregon, Mr.

922 Schrader, for 5 minutes.

923 Mr. {Schrader.} Thank you, Mr. Chairman. I appreciate

924 it.

How does the Agency currently and then under your 925 926 interpretation of the new discussion draft balance individual 927 risk and responsibility versus, you know, absolute risk, if 928 you will, posed by certain chemicals? 929 Mr. {Jones.} That is a good question, Congressman. 930 Right now we are looking at a compound that is used as a 931 paint stripper, and it has actually resulted in deaths across 932 the country over the last 15 years, and so arguably--and it 933 results in deaths because people sometimes use it in an enclosed space, and so if you--it is theoretically possible 934 935 that we could mitigate that risk by a labeling restriction, 936 although when you look there actually is a labeling 937 restriction right now although the fine print is guite fine, 938 and so you try to struggle with the effectiveness of giving 939 people information to protect themselves versus what may be 940 the reality is to whether or not people avail themselves of 941 that, and so it is something that we right now are struggling 942 with, with a chemical that we have made a priority compound 943 because, you know, individuals do have some responsibility 944 with respect to protecting themselves, but at the same time,

945 if past is prologue and giving information may not be 946 effective, we think we have the ability to protect people 947 from themselves.

948 Mr. {Schrader.} I think one of the struggles this committee is going to have and the Congress writ large is 949 950 balancing that personal responsibility. If people are 951 allergic to certain things and most people are not allergic 952 to, does that make that a toxic substance generally speaking. 953 So I think we are going to have a lot of work to do to find 954 out what that appropriate balance is. This is still the United States of America and people do bear personal 955 956 responsibility for their own health and well-being, and 957 labeling, albeit small or large, hopefully adequately, 958 demonstrating what potential harm it may cause to certain 959 subpopulation is important but the real world is anything in excess is probably toxic, in popular terms, carcinogenic. 960 961 Everything is carcinogenic these days. I think we have to be 962 thoughtful and I would hop the EPA would balance their 963 rulemaking with whatever legislation we have going forward. I am interested in the cost-effectiveness discussion. 964 You are interested in apparently more leeway than is now 965

966 granted under this legislation. I would probably be against 967 that. My concern is that costs should be taken into account. 968 We have a Superfund site in my state where EPA's 969 interpretation has gotten to where if one individual sort of maybe could have ingested a certain amount of fish on a daily 970 971 basis, way in excess of what any person would do, even tribal 972 members, that at a level that is way below the current 973 toxicity standards, that that would pose a significant risk 974 and needs to be mitigated by extremely expensive 975 alternatives, and the judgment I have seen so far from EPA is that they want to have a very expensive alternative to what 976 977 could be a simpler solution to I think a very exaggerated 978 risk. So I would hope that you would take this into account. 979 I hope that the legislation does not reduce the cost. In 980 fact, to me it seems pretty clear. You know, when you are 981 determining the risk, okay, cost should not perhaps be part of the discussion, but certainly, certainly, absolutely, 100 982 983 percent cost-effectiveness should be part of, a major part of 984 the solution, and I would fight against any language that 985 said cost should be just a consideration. That, to your point, is a loophole you could drive a truck through at the 986

987 end of the day. So I hope you would be at least open to the 988 current legislation as currently written.

989 Mr. {Jones.} We think it is very important for cost to 990 be considered in the risk management. It is about how it should be considered, and as I was saying, right now it is 991 992 not clear if it needs to be considered in a literal balancing of cost and benefits, and that we have stated numerous times 993 994 how challenging that is for chemicals where it is always 995 possible to estimate cost. It is often not possible to give 996 a numeric monetization to the benefit.

997 Mr. {Schrader.} Well, if you can't monetize it that 998 what can't be measured should probably be done. I mean, at 999 the end of the day, there has to be--everyone is susceptible. 1000 There are going to be some persons, some individuals, some 1001 child, some remote genetic configuration of any given 1002 individual that is going to be at risk with any given chemical or food substance, whether it is deemed safe or not, 1003 1004 and I think it is extremely important not to get wrapped 1005 around the axle on having completely irrelevant, with all due 1006 respect, solutions that are not actually benefit to the 1007 population writ large.

As a veterinarian, it is all about epidemiology. You are not going to save everybody at the end of the day, and we have to understand that, and I think America in this 21st century has to become sophisticated enough to understand where is the maximum risk exposure.

1013 With that, I would like to yield the balance of my time 1014 to the chairman of the committee--or ranking member. Excuse 1015 me.

1016 Mr. {Shimkus.} Yeah, you don't want to give it to me--1017 no, you might want to give it to me.

1018 Mr. {Tonko.} Thank you. I thank the gentleman for 1019 yielding.

1020 I would like to turn briefly to a concern I have that 1021 the draft is too specific about how the Agency should conduct 1022 science. Agency decisions must be transparent including those about science, but in my opinion, these are decisions 1023 best left to technical experts. This draft includes 1024 requirements that EPA act based on a specific definition of 1025 1026 the weight of the scientific evidence and requires EPA to 1027 consider a lengthy list of factors including sponsor organizations, uncertainty and more. 1028

1029 So Mr. Jones, when these scientific requirements are 1030 included in the statute, does that open EPA's use of science 1031 up to litigation? 1032 Mr. {Jones.} So any requirement that you have to do, 1033 you then either--if you don't do it, you are open to 1034 litigation. I think that the science requirement that most 1035 troubles us is the consideration of a threshold effect, which 1036 is something that we do right now, but it is certainly 1037 possible that in 10, 15 or 20 years, it is not even part of 1038 the scientific, you know, lexicon. And so boxing us into 1039 things that may become obsolete in the future scientifically 1040 are the kinds of things we would like to generally avoid. 1041 Mr. {Tonko.} Thank you, and I share those concerns, and 1042 I yield back. 1043 Mr. {Shimkus.} The gentleman yields back his time. The chair now recognizes the gentleman from Ohio, Mr. Johnson, 1044 for 5 minutes. 1045 1046 Mr. {Johnson.} Thank you, Mr. Chairman. 1047 Administrator Jones, about a year ago, you testified 1048 before this committee on TSCA reform. You may remember at 1049 that meeting, I expressed my concern to you that TSCA

1050 reporting requirements seemed to incentivize manufacturers, 1051 for example, in the electronics industry, to landfill 1052 byproducts instead of recycling them, even when those 1053 byproducts are rich in recyclable metals and other valuable 1054 materials--copper, for example. In other words, we are 1055 making it more cost-effective for manufacturers to put that 1056 stuff in the dirt than to recycle it, save money, create 1057 jobs, and be more environmentally conscious. You may also remember that last October I sent 1058 1059 Administrator McCarthy a letter asking the EPA to complete 1060 its analysis of data collected during the 2012 chemical data 1061 reporting, or the CDR cycle, with the idea that such an 1062 analysis would help EPA reassess the need for CDR information 1063 in future reporting cycles. In December I received a 1064 response from Administrator McCarthy that the analysis would be completed by early 2015. It is now April, and no analysis 1065 has been finalized, and while the EPA has had talks with my 1066 1067 staff, and I know that there has been some exchange of 1068 information with industry, it has not provided the 1069 electronics industry nor the public with any new information 1070 for some time now. So because it appears that this analysis

1071 is ongoing, I remain hopeful that the EPA still has the 1072 opportunity to safely incentivize the recycling of byproducts 1073 and render any other options to solve this problem 1074 unnecessary. 1075 But the first step must be the release of the analysis of 2012 CDR byproducts. Can you tell me when that data will 1076 1077 be released? 1078 Mr. {Jones.} Thanks, Congressman, and thank you for 1079 raising this issue to our attention. We have spent a fair 1080 amount of time evaluating the issue that you brought to our 1081 attention. We have begun to communicate with your staff as 1082 well as the electronics industry the results of our analysis. 1083 I would be reluctant to give a date on the release of the 1084 analysis before checking with my staff, but we are very close 1085 to being able to give an answer to the question that you 1086 raised. Mr. {Schrader.} Okay. Administrator McCarthy said 1087 1088 early 2015. Is that still a projection? Are looking at the 1089 first half of this year or--1090 Mr. {Jones.} It is the first half of this year. 1091 Mr. {Schrader.} Okay. All right. Well, I look forward

1092 to getting that. I appreciate that.

1093 What is the EPA's cost for doing the analysis that they

1094 do? Is it pretty consistent or does the cost vary from 1095 chemical to chemical?

1096 Mr. {Jones.} It is going to vary pretty significantly 1097 from chemical to chemical.

1098 Mr. {Schrader.} Okay. Can you give us an example? 1099 Mr. {Jones.} Yes. So the first five chemicals that we 1100 looked at, we project that the regulation for those that we 1101 think bear consideration of regulation will cost about a 1102 million and a half dollars and the analysis will have been a 1103 million dollars. That applies to three of them, and so the 1104 chemicals that demonstrated some risk are significantly more 1105 expensive to do than the two chemicals which did not 1106 demonstrate any risk. So when you find no risk, it is 1107 relatively cheap. There we estimated about a million 1108 dollars, so actually much of the cost is associated with the 1109 regulatory requirements of the analysis necessary to support 1110 a regulation.

1111 Mr. {Schrader.} You just said something that maybe I 1112 misunderstood you. Why would you be considering regulating a

1113 chemical that provides no risk anyway? 1114 Mr. {Jones.} I am sorry. I must have stated it 1115 backwards. 1116 The chemicals that demonstrated risk are the ones that 1117 we are doing regulatory analysis for to support a potential 1118 regulation. 1119 Mr. {Schrader.} Okay. All right. 1120 The discussion draft gives the EPA to select a chemical 1121 substance for risk evaluation under TSCA section 6. Would 1122 the EPA rely on information that is currently available to 1123 the Agency to make those selections? 1124 Mr. {Jones.} That is now we would intend to--1125 Mr. {Schrader.} That is how you put those in the risk 1126 category? 1127 Mr. {Jones.} Yes. Mr. {Schrader.} Okay. I think I have only got 34 1128 seconds left, and I can't get this last one in. Mr. 1129 1130 Chairman, I will yield back some of my time. 1131 Mr. {Shimkus.} The gentleman yields back his time. The 1132 chair now recognizes the gentleman from Texas, Mr. Green, for 5 minutes. 1133

1134 Mr. {Green.} I am sitting in as the ranking member. 1135 Mr. Tonko had to go, although from Paul from New York doesn't 1136 really want me from Texas doing it. 1137 Mr. {Shimkus.} You better take down that placard 1138 because you might hurt him. 1139 Mr. {Green.} Yeah, I don't want to get him in trouble. 1140 Thank you for being here. I particularly want to thank 1141 Chairman Shimkus and Ranking Member Tonko and our ranking 1142 member and chair of the full committee for working on this 1143 issue. It has been frustrated because it has been a law 1144 since 1976, and I know for the last two terms this 1145 subcommittee has tried to see how we could deal with it, but 1146 it sounds like, you know, we will go small and see what we 1147 can do and do just problem-solving, which I think is a great 1148 way to go. 1149 If enacted, would the TSCA Modernization Act improve 1150 EPA's ability to make a risk determination and a risk 1151 management plan for existing chemicals?

Mr. {Jones.} That is an interesting question. For the way it is structured right now, because the only things-because the way the fees don't come to the Agency for

1155 industry-submitted requests, it would absolutely make it 1156 clearer what we had to do and how many. We have to do 1157 whatever they submitted to us. But because we are not 1158 getting the fees, I think it would crowd out our ability to 1159 initiate any on our own. Now, if there is a solution that 1160 allows the fees to come to EPA, then I think it would clearly 1161 allow us to have more pace to existing chemicals program. 1162 Mr. {Green.} Okay. Would the discussion draft retain 1163 the current TSCA timing of preemption of state and local 1164 action? 1165 Mr. {Jones.} Basically, yeah, it would retain the--it would eliminate the -- it would basically be similar to what is 1166 currently required in TSCA, marginally different. 1167 1168 Mr. {Green.} Under the discussion draft, would risk determination be based solely on health and safety factors 1169 1170 without consideration of cost? 1171 Mr. {Jones.} The risk evaluation would, yes. 1172 Mr. {Green.} Currently, the EPA is allowed to disclose 1173 confidential business information to state and local 1174 government officials. Is that part of this package? Mr. {Jones.} Currently it is quite difficult to do that 1175

1176	but under this provision, the provision in the discussion
1177	draft, it would make it quite straightforward to do that.
1178	Mr. {Green.} Okay. Will the discussion draft allow EPA
1179	to disclose the confidential business information to the
1180	well, strike that. Under current TSCA, is EPA allowed to
1181	disclose CBI to a treating doctor or a healthcare
1182	professional?
1183	Mr. {Jones.} It is quitethat is what I was saying.
1184	It is quite burdensome for us to do that right now, which is
1185	something that
1186	Mr. {Green.} Would this discussion draft help with
1187	that?
1188	Mr. {Jones.} Yes.
1189	Mr. {Green.} Would the discussion draft authorize the
1190	EPA to disclosewell, I take that back again. Under current
1191	law, is there any limit to the length of time for
1192	confidential business information claim?
1193	Mr. {Jones.} No.
1194	Mr. {Green.} Under the discussion draft, would there be
1195	any time limits?
1196	Mr. {Jones.} Yes, 10 years.

1197 Mr. {Green.} Okay. The discussion draft creates a new 1198 term, ``potentially exposed subpopulations.'' Under the 1199 definition provided in the discussion draft, would the 1200 thousands of chemical plants that I have and the people that 1201 work there and the people that live around it in our district 1202 be covered under the definition of potentially exposed 1203 subpopulations? 1204 Mr. {Jones.} It is certainly possible that they would 1205 be, yes. 1206 Mr. {Green.} Now, obviously you want those jobs there but we also want to make sure that the products they are 1207 1208 producing that our country needs are safe as possible. In 1209 your testimony, you note the discussion draft lacks a 1210 sustained source of funding for the chemical safety 1211 management, which goes back to the funding. Would you 1212 recommend to our subcommittee the best way to address that 1213 concern? 1214 Mr. {Jones.} I think it is a relatively straightforward 1215 fix that has the funding that is designated here going to the 1216 EPA, which right now it would not go to the EPA.

1217 Mr. {Green.} And I think that is something we will

1218	consider. Are there current statutes that provide a
1219	sustained source of funding that could be used as a model for
1220	TSCA reform?
1221	Mr. {Jones.} Yeah, both the drug lawPDUFA is the
1222	acronymor the pesticide law, the Pesticide Registration
1223	Improvement Act, both have funding mechanisms.
1224	Mr. {Green.} You state in your testimony that EPA
1225	strongly feels that any update to TSCA must provide the
1226	agency with the ability to make timely decisions and the
1227	ability to take action to address that risk. Do you believe
1228	that the discussion draft provides the agency with the needed
1229	authority to make those timely decisions?
1230	Mr. {Jones.} The timeliness is clear. As I said
1231	earlier, I think that the ambition is quite impressive and
1232	perhaps not manageable. I think the part that I am
1233	struggling is looking for more clarity as to exactly what the
1234	risk management standard is so we are not fighting in
1235	litigation forever about what it actually means.
1236	Mr. {Green.} And I agree. I would hope when we finish
1237	it, we give the clarity that you need so there is no question
1238	at all. In fact, EPA is downstairs in the Energy and Power

1239	Subcommittee so you all are regular guests here in our
1240	committee.
1241	Mr. {Jones.} We carpooled over.
1242	Mr. {Green.} But any suggestions I know we would all
1243	appreciate that. And do you believe the discussion draft
1244	gives the EPA to authority to address the identified risk?
1245	If not, what changes would we need to ensure the Agency has
1246	that authority?
1247	Mr. {Jones.} Again, that goes back to clarity of what
1248	the risk management standard is is important.
1249	Mr. {Green.} Thank you, Mr. Chairman. I know I am over
1250	time. I appreciate it.
1251	Mr. {Shimkus.} The gentleman yields back his time. The
1252	chair will now look to my colleague from Indiana, Mr.
1253	Bucshon. Do you waive?
1254	Mr. {Bucshon.} I waive.
1255	Mr. {Shimkus.} The chair now recognizes the gentlelady
1256	from Colorado, Ms. DeGette. It is good to have her back.
1257	She was very active last Congress, and we are glad to see her
1258	here with us.
1259	Ms. {DeGette.} Thank you very much, Mr. Chairman. I

1260 really appreciate you having this hearing, but even more so, 1261 I appreciate the amount you have worked with Mr. Green, 1262 myself, Mr. Tonko and others on really trying to make 1263 progress on this path to TSCA reform. It is not easy as we 1264 all had been saying. If it was easy, it wouldn't have taken 1265 us 30 years to fix it.

1266 And thank you, Assistant Administrator Jones, for coming 1267 over to give us some thoughts this morning. I want to start 1268 by looking at EPA's ability to require testing of chemicals 1269 under the draft. This discussion draft includes an important 1270 change to EPA's authority under section 4 of TSCA by 1271 empowering the EPA to require testing through order rather 1272 than rulemaking.

1273 So if you can talk to us about how order authority will 1274 improve your ability to require testing under section 4, that 1275 would be great.

Mr. {Jones.} Sure. Right now we are required to do a rule if we want to compel the generation of health and safety data for a chemical, and we are also required to make a finding that we have some reason to believe there may be an unreasonable adverse effect for such chemicals, so you get

into this kind of a catch-22. You want the data because you 1281 1282 don't know but you need to know something before you compel 1283 it, and then you have to do a rule, and rulemaking is a very 1284 long process and so it can take many, many years. So an 1285 order authority would allow us to move much more quickly to 1286 require generation of health and safety data. 1287 Ms. {DeGette.} Do you have any sense about on an 1288 average how much more guickly that would be? 1289 Mr. {Jones.} Well, in our pesticides program, we have 1290 order authority and have had it for 40 years, and when we 1291 find that there is data that we need to require, we are able 1292 to issue orders in matters of months as opposed to 4 or 5 1293 years. 1294 Ms. {DeGette.} Okay. Now, that change was one that I

had sought in section 4 but this draft doesn't seem to address the catch-22 that EPA has long faced, and you talk a little about it. It seems that under this draft, the EPA would still have to find that a chemical might present an unreasonable risk before they were required--before they could require testing, and that is what you were just talking about.

Mr. {Jones.} So the way we have read the discussion draft, Congresswoman, is that to issue an order, we don't need to make that finding, so that seems to be addressed. It is in the context of to initiate a risk evaluation, we need to have some reason to believe the exposure exceeds the hazard.

Ms. {DeGette.} And so how do you think the language, or do you think the language can be adjusted in this discussion draft to reflect that issue?

1311 Mr. {Jones.} I think it would be relatively

1312 straightforward to do that instead of having some reason to 1313 believe exposure exceeds hazard, have some reason to believe 1314 there is exposure, have some reason to believe there is 1315 hazard.

1313 Hazaru.

1316 Ms. {DeGette.} Okay. So it is the ``exceeds hazard'' 1317 that is the issue?

1318 Mr. {Jones.} Yes, I think so.

1319 Ms. {DeGette.} If you could work with us to supplement 1320 your response to give us some technical assistance on that, 1321 that would be really helpful. We would appreciate it. 1322 In addition to granting the EPA order authority to

1323	require testing, the discussion draft also includes a
1324	provision to allow manufacturers to request that EPA evaluate
1325	their chemicals for safety. The discussion draft requires
1326	the EPA to make a finding on any evaluations requested by
1327	companies within 6 months. Is that going to be enough time
1328	to perform a robust evaluation of a chemical?
1329	Mr. {Jones.} I don't think so, no.
1330	Ms. {DeGette.} How long does the evaluation of a
1331	chemical usually take?
1332	Mr. {Jones.} It usually takes a couple of years, and
1333	this was the conversation the chairman and I were having that
1334	the discussion draft doesn't require the manufacturers to
1335	submit all the data necessary to do an evaluation. If it
1336	did, it would still require a couple of years. And so they
1337	could just say I want you to evaluate my chemical. The other
1338	thing is that when there is a controversy around the
1339	chemical, it is often the case that EPA's interpretation of
1340	the data doesn't agree with the manufacturer's.
1341	Ms. {DeGette.} So do you think there is some language
1342	we could put together to tighten that up a little bit?
1343	Mr. {Jones.} It would seem like it is more about how

1344 much time the Agency should have to do--1345 Ms. {DeGette.} So maybe, Mr. Chairman, that is 1346 something we can talk about as we go forward. 1347 Mr. {Shimkus.} Would the gentlelady yield? 1348 Ms. {DeGette.} I would be happy to. 1349 Mr. {Shimkus.} I still think there is this debate about 1350 what is industry going to provide, and that was the whole 1351 part. 1352 Ms. {DeGette.} Right. 1353 Mr. {Shimkus.} If they are providing a lot of data, then the timelines may be legit, so we will visit that. 1354 1355 Ms. {DeGette.} Okay. Good. All right. 1356 The last thing is that the discussion draft proposes 1357 amending section 9 of TSCA to allow the EPA to set fees to 1358 help defray the costs of additional chemical testing but it doesn't flag funds to be used specifically for that purpose. 1359 1360 So my question is, does the Office of Chemical Safety and 1361 Pollution Prevention have sufficient funds appropriated to 1362 undertake additional testing of new chemicals under TSCA? 1363 Mr. {Jones.} Not as written in the discussion draft. Ms. {DeGette.} So if we had some kind of a dedicated 1364

1365 fund rather than just solely relying on appropriations, would 1366 that be of assistance? 1367 Mr. {Jones.} Yes, it would. 1368 Ms. {DeGette.} Thank you, Mr. Chairman. Mr. {Shimkus.} The gentlelady's time is expired. 1369 The chair now turns to Mr. Cramer from North Dakota for 5 1370 1371 minutes. Do you waive? 1372 Mr. {Cramer.} I would yield to Mr. Hudson. 1373 Mr. {Shimkus.} The gentleman has yielded to Mr. Hudson, 1374 who is recognized for 5 minutes. 1375 Mr. {Hudson.} Thank you, Mr. Chairman. 1376 Thank you for being here today. I appreciate your 1377 testimony. It has been very informative. 1378 My first question: TSCA as amended by the discussion 1379 draft requires that the agency have a need for testing and 1380 exposure information before it imposes a requirement on 1381 manufacturers and processors to develop that information. Is 1382 that a good requirement? 1383 Mr. {Jones.} I believe so, yes. 1384 Mr. {Hudson.} All right. Last year you asked that each chemical evaluation have a deadline for completion. Are the 1385

- 1386 deadlines in our bill about right for that?
- 1387 Mr. {Jones.} I rarely say this: They are a little too
- 1388 short.
- 1389 Mr. {Hudson.} Really? Well, what do you think they 1390 ought to be?
- 1391 Mr. {Jones.} Well, I think that we can complete
- 1392 assessments within 3 years. I don't think we can even with
- 1393 industry-submitted data complete an industry-submitted
- 1394 assessment in 6 months. As much as I would love to do a
- 1395 rulemaking in 6 months, I think we probably need upwards of 2
- 1396 years to do a rulemaking.
- Mr. {Hudson.} EPA has authorized some 90 chemicals as TSCA work plan chemicals. Does the discussion require a change to that program?
- 1400 Mr. {Jones.} It requires us to make a finding that is 1401 above and beyond what we did in the identification of the 1402 priority chemicals.
- Mr. {Hudson.} Well, would work plan chemicals likely be selected for risk evaluations under the House discussion draft?
- 1406 Mr. {Jones.} They would likely be but, again, we would

have to do one additional step that we have not done

1407

1408 heretofore, make a determination that we think it is likely 1409 or possible that the exposure exceeds the hazard, which we 1410 have not done. 1411 Mr. {Hudson.} Gotcha. I have got a question as far as 1412 fees, collection of fees currently. How does the Agency 1413 currently collect user fees under TSCA? 1414 Mr. {Jones.} We only have a few right now for the 1415 submission of a new chemical under the pre-manufacturer 1416 notification program. Those fees don't come to EPA either, 1417 so except for some small businesses, manufacturers when they submit a new chemical to EPA for review submits a fee with 1418 1419 that. 1420 Mr. {Hudson.} And those go back to the Treasury? 1421 Mr. {Jones.} They go back to the Treasury. 1422 Mr. {Hudson.} What is your budget breakdown by category for individual sections of TSCA? 1423 1424 Mr. {Jones.} I would need to get back to you on that 1425 but we could provide that pretty quickly. 1426 Mr. {Hudson.} I would appreciate it if you would do that. What is the EPA budget in both funding and FTEs for 1427

chemical review under section 5 and under section 6 of TSCA? 1428 1429 Mr. {Jones.} Again, that would be part of what we would 1430 get back to you on, overall budget breakdown between existing 1431 chemicals and new chemicals. 1432 Mr. {Hudson.} Okay. Well, I would appreciate that 1433 information, and I thank you. 1434 Mr. {Shimkus.} Would the gentleman yield? 1435 Mr. {Hudson.} I yield back to the chairman. 1436 Mr. {Shimkus.} Just a follow-up. So on new chemicals, 1437 you have 90 days, and then with the possibility of an additional 90 days? 1438 1439 Mr. {Jones.} Um-hum. 1440 Mr. {Shimkus.} And so we are saying on existing chemicals, it will take 3 years? That is just part of the 1441 1442 date we are having. 1443 Mr. {Jones.} Yes. 1444 Mr. {Shimkus.} You will have to explain to me why--not 1445 now but you will have to explain to me why that is, and with 1446 that, I yield back the time and now, she has been very 1447 patient, my colleague from California, Ms. Capps, for 5 1448 minutes.

1449 Mrs. {Capps.} Thank you, Mr. Chairman, first of all, 1450 for holding the hearing, and our witness for your testimony. 1451 Under current law, TSCA has used an ``unreasonable risk'' standard to evaluate the safety of a chemical. This 1452 1453 is understood to be a cost-benefit standard, which in effect 1454 requires the Agency to balance the economic value of a 1455 chemical against the adverse health effects such as cancer, 1456 autism. Besides posing serious ethical problems, this 1457 approach has also proven to be unworkable.

1458 Mr. Jones, what is the impact of this cost-benefit 1459 standard in the context of TSCA?

Mr. {Jones.} Well, as I have mentioned, it is often 1460 1461 very difficult for certain health outcomes to the way in 1462 which we do risk assessment to monetize them. Some we are 1463 able to. There are some carcinogens which we are able to 1464 monetize. There are some pollutants like particulate matter 1465 where we are able to monetize. In the case of a chemical 1466 that we are looking at right now where death is the outcome, 1467 we can monetize that. There are some outcomes the way our risk assessment is designed, we are not able to monetize 1468 them, and so our ability to say that these benefits literally 1469

1470	outweigh these costs is challenging. It is not impossible
1471	but it creates a challenge for us.
1472	Mrs. {Capps.} So since 2009, there has been widespread
1473	agreement that this cost-benefit standard does need to be
1474	abandoned. This subcommittee has repeatedly received
1475	testimony that TSCA's current safety standard is failing to
1476	protect the general public and particularly vulnerable
1477	populations. EPA, the American Chemistry Council, even oil
1478	refineries have all stated that cost should not be part of
1479	safety determinations under TSCA. I welcome the changes in
1480	the discussion draft to explicitly exclude costs from risk
1481	evaluations but I am not sure they go far enough.
1482	So my question, Mr. Jones, is: do you think changes are
1483	needed in this draft to ensure the safety of chemicals as
1484	evaluated against a purely health standard?
1485	Mr. {Jones.} Well, what I said so far today is that
1486	right now it is just ambiguous as to what the standard is,
1487	and that I think is critically important so we don't spend,
1488	if this were to become law, the next 30 years litigating what
1489	the standard is. The Administration has said that the safety
1490	evaluation should be risk-based but the Administration has

1491 also said that cost should be a consideration in the risk 1492 management. 1493 Mrs. {Capps.} Right. I hope you will work with this 1494 committee because we intend to, I hope, move forward to 1495 ensure the language gives effect to that kind of intent. 1496 Another important component of the safety standard in 1497 any TSCA proposal is protection for vulnerable populations. 1498 Vulnerable populations include infants and children, the 1499 elderly and disabled, workers, and those living near chemical 1500 facilities. In their 2009 report, Science and Decisions, the 1501 National Academy of Science recommended that vulnerable populations should receive special attention at all stages of 1502 1503 the risk assessment process. 1504 Mr. Jones, do you agree that it is important to address

1505 risks to vulnerable populations when managing chemical risks 1506 under TSCA?

1507 Mr. {Jones.} Yes.

1508 Mrs. {Capps.} I am pleased to see this draft includes 1509 an explicit protection for vulnerable populations blocking 1510 EPA from finding that a chemical does not present an 1511 unreasonable risk if the agency finds that the chemical

1512 presents an unreasonable risk for a vulnerable subpopulation. 1513 In other words, if a chemical fails to meet the standard for a subpopulation, it doesn't meet the standard, period. 1514 1515 Mr. Jones, do you think that requirement is going to 1516 provide the protection that we need for vulnerable 1517 populations? 1518 Mr. {Jones.} It is interesting, Congresswoman Capps. 1519 When we make the determination that a chemical doesn't pose 1520 an unreasonable risk, we have to make the finding you 1521 described, and this just goes back to the earlier comments 1522 for when what the actual safety standard is when we find that there is risk is not clear, and for that reason it is not 1523 1524 clear how vulnerable populations would be included in that, 1525 so when we find there is a risk. 1526 Mrs. {Capps.} So we need more clarity? 1527 Mr. {Jones.} There needs more clarity there. 1528 Mrs. {Capps.} Yes. And I appreciate the efforts made 1529 in this draft to ensure, and I can see now it is important to 1530 emphasize the word ``draft.'' It probably does need to be 1531 changed along the way. Costs are left out of safety evaluations and that vulnerable populations are protected. 1532

1533 This is sort of we are this far on it but I hope we can 1534 continue to work to improve this draft. I applaud the 1535 efforts that we have made so far but we have a ways to go to 1536 make sure that we move chemical regulation forward, and I 1537 yield back.

1538 Mr. {Shimkus.} The gentlelady yields back her time. 1539 Seeing no other members asking for questions, we do want 1540 to thank you for, it is obviously not long in congressional 1541 time but a legislative hearing, and we want to thank the 1542 members for being very diligent and involved and engaging in 1543 your responses. We look forward to working with you, and 1544 with that, we will dismiss you and ask for the second panel 1545 to come forward.

1546 Mr. {Jones.} Thank you.

Mr. {Shimkus.} We would like to start. We want to thank the second panel for coming and appreciate you sitting through the first round. Hopefully a lot of questions will be generated based upon the comments. The way I would like to do it is, I will just introduce one at a time when their time comes for the opening statements, and again, welcome. A lot of them are familiar faces that we have seen here

1554	numerous times, so friends of the committee, I would say.
1555	First, we would like to welcome Mr. Mike Walls, who is
1556	the Vice President of Regulatory and Technical Affairs with
1557	the American Chemistry Council. Your full statement is in
1558	the record. You have 5 minutes, and you are recognized.

1559	^STATEMENTS OF MICHAEL P. WALLS, VICE PRESIDENT OF REGULATORY
1560	AND TECHNICAL AFFAIRS, AMERICAN CHEMISTRY COUNCIL; DR. BETH
1561	BOSLEY, PRESIDENT, BORON SPECIALTIES, LLC, ON BEHALF OF THE
1562	SOCIETY OF CHEMICAL MANUFACTURERS AND AFFILIATES; JENNIFER
1563	THOMAS, SENIOR DIRECTOR, FEDERAL GOVERNMENT AFFAIRS, ALLIANCE
1564	OF AUTOMOBILE MANUFACTURERS; AND ANDY IGREJAS, DIRECTOR,
1565	SAFER CHEMICALS, HEALTHY FAMILIES
1566	STATEMENT OF MICHAEL P. WALLS
1567	} Mr. {Walls.} Good morning, Mr. Shimkus, Mr. Tonko, and
1568	members of the

Mr. {Shimkus.} And just if you could pull that a little 1570 bit closer.

1571 Mr. {Walls.} How is that? I don't want to break 1572 anybody's eardrums.

1573 Thank you again for the invitation to be here today. I 1574 am very happy to testify today in support of the bipartisan 1575 discussion draft.

1576 ACC strongly supports efforts to reform TSCA. Over the

1577 years, problems with implementation of the current statute 1578 have eroded public confidence in the federal regulatory 1579 system, contributed to misperceptions about the safety of 1580 chemicals, and created uncertainty throughout interstate 1581 commerce.

1582 The discussion draft is a significant milestone in the 1583 TSCA reform debate. For the first time, there is now 1584 bipartisan reform measures before each House of Congress, and 1585 while the debate over TSCA reform certainly doesn't end with 1586 this hearing, there is now a very real opportunity to achieve TSCA reform this year, and we at ACC are very encouraged by 1587 1588 the very positive comments that members of this subcommittee 1589 have made both on the process and the substance of the draft. 1590 Now, in 2009, ACC published a set of 10 fundamental 1591 principles for TSCA reform. The discussion draft, like S. 697, which is pending in the Senate, fully addresses all our 1592 1593 principles. The draft addresses key issues and shortcomings 1594 in TSCA, and among the most important elements are that the draft requires that EPA evaluate risks only on the basis of 1595 1596 health and environmental considerations. That was a key problem that has hampered implementation of the current Act 1597

1598 to date.

Under the draft, cost and benefit considerations are relevant only in deciding what regulatory option EPA will impose to control risks. We believe the draft strengthens EPA's authority to mandate the generation of new information on chemicals. The draft also protects sensitive commercial information from disclosure while requiring appropriate upfront substantiation of those claims.

1606 The draft also balances the interests of the state and 1607 federal governments by promoting a robust, uniform national 1608 chemical regulatory system.

1609 As the subcommittee continues its discussion, some 1610 elements of the draft do require some additional

1611 clarifications. We think there is a need for additional

1612 detail and direction to EPA on the manufacturer risk

1613 initiated--sorry--the manufacturer-initiated risk evaluation

1614 process. I think you heard comments to that effect from Mr.

1615 Jones. We think it is particularly important that Congress

1616 provide clear direction and clearly articulate its

1617 expectations for that process, and at a minimum, EPA should

1618 be required to promulgate rules or appropriate guidance so

1619 that all stakeholders understand how that process can produce 1620 risk evaluations that are timely, of high guality and are 1621 reliable. 1622 We also think it is necessary to clarify the interplay between section 6A and 6B and the presence or absence of an 1623 1624 appropriate risk management rule. This was one of the 1625 elements Mr. Jones mentioned at the conclusion of his 1626 testimony. 1627 ACC also believes that EPA must have access to 1628 appropriate resources to implement a reformed TSCA. Under 1629 the draft, TSCA fee revenue is deposed to the general Treasury. We believe those funds need to be returned to EPA. 1630 1631 The draft also allows state governments to adopt regulations identical to those promulgated by EPA in certain 1632 1633 cases. It would be helpful if the degree to which states may depart from the federal approach in enforcing those 1634 regulations, if at all, should be clarified. 1635 1636 Again, the bipartisan discussion draft is a significant 1637 step toward achieving TSCA reform this year. We look forward 1638 to working with all members of this subcommittee to ensure 1639 that TSCA reform builds confidence in the U.S. chemical

1640	regulatory system, protects health and the enforcement from
1641	significant risks, and meets the commercial and competitive
1642	interests of the U.S. chemical industry and the national
1643	economy.
1644	Thank you again for the opportunity to testify. I am
1645	happy to respond to questions.
1646	[The prepared statement of Mr. Walls follows:]

1648 Mr. {Shimkus.} Thank you.

1649 Next I would like to turn to Dr. Beth Bosley, President

1650 of Boron Specialties, on behalf of the Society of Chemical

1651 Manufacturers and Affiliates. She has testified before.

1652 Welcome back, and you are recognized for 5 minutes.

1653 STATEMENT OF BETH BOSLEY

1654 Ms. {Bosley.} Thanks very much. Good morning, Chairman } 1655 Shimkus and Ranking Member Tonko, and everyone on the subcommittee, and thanks also for having me back to 1656 1657 Washington to discuss TSCA, one of my favorite subjects. Ιt 1658 has been really refreshing to hear so much positive 1659 statements being put forth by both the Democrats and 1660 Republicans on this issue, and we really applaud all the 1661 efforts to modernize TSCA. It covers such a wide variety of chemicals and applications, and it really impacts a huge 1662 1663 swath of our economy, so it is really important, and given the range of interested parties, it is remarkable how much 1664 1665 alignment has been achieved. It is a very complicated statute, and you have worked pretty hard not to make it more 1666 complicated, so I applaud that as well. 1667

I would just like to highlight a few things that I think are important in the discussion draft. The safety standard, I think it corrects--as we have already heard today, it corrects the fundamental flaw in the current TSCA that

1672 requires you to take cost into account. In this case, 1673 protection of human health and the environment is really the 1674 only driver for the safety standard, and that is a great 1675 improvement. EPA will make very different decisions under 1676 section 6 than it has before, and it will allow policy and 1677 emerging science to inform protective determinations 1678 regarding these chemicals.

1679 For new chemicals, I have talked guite a bit I think 1680 here before that I think the new chemicals process works very 1681 well, and I would like to remain basically as it is. It is 1682 one of the more important parts of the statute. It drives 1683 our environment, drives protection of our environment and our 1684 economy. Experience has taught us that new chemicals can be 1685 greener, and of course, we must continue to innovate because 1686 we live in a global economy now. If we want to promote innovation and develop greener chemistries, we really must 1687 1688 remain--section 5 must really remain efficient, predictable 1689 and affordable.

1690 We are also interested in timely access to the market, 1691 and the 90-day review window has proven sufficient in most 1692 cases. In some cases, EPA has to suspend or give itself

1693 another 90 days but in fact EPA often completes its review 1694 after day 22, which is really very early. It depends on how 1695 much information they are given but after day 22 is often. 1696 We would certainly like to be able to go to market after day 1697 22 as well.

One area that TSCA hasn't worked, and we have heard 1698 1699 about this a number of times already this morning, is with 1700 existing chemicals, but I think the discussion draft goes a 1701 long way to really solve the problems with existing 1702 chemicals. It can ask for data under section 4 really 1703 whenever it thinks it is necessary to conduct the risk 1704 evaluation. It doesn't have to make a finding, and that is a 1705 really get improvement.

We do support a more comprehensive review of existing chemicals, and since there is no detailed screening process outlined in the bill, we are assuming EPA would go forward with its work plan chemicals as it has to date.

1710 We do also support deadlines for this review. I am not 1711 sure how long it takes but I would say EPA probably has a 1712 good estimate of how long existing chemicals take to review, 1713 and we know that deadlines work well in new chemicals, so

1714 they should work well in existing chemicals, but the 1715 deadlines and the workload really has to be achievable. Under section 8 for the reporting requirements, one of 1716 1717 the most important factors we see there is an inventory reset 1718 that as we have heard already today, again, there is over 1719 80,000 chemicals on the inventory but only 7,700 were 1720 reported on in the most recent CDR. That is a big disparity 1721 between what is in commerce and what is not in commerce. 1722 Currently as a manufacturer, also I report on exposures 1723 of chemicals to my employees but then I also have to estimate 1724 exposures to my customers' employees, and that is pretty hard 1725 for me to do, especially as a small business, so I would 1726 think process of reporting would be very important to add to 1727 this--requiring process of reporting would be very important 1728 language to add. 1729 Confidential business information is really important 1730 for all U.S. manufacturers but especially small businesses

1731 like mine. CBI allows us to pursue research and market 1732 development without advertising to the world exactly what we 1733 are doing. Even so, we really appreciate that we must 1734 proceed with as much transparency as possible, and I think

1735	the re-substantiation after 10 years is an excellent addition
1736	to the current draft.
1737	Resources and fees, as we have all heard, EPA needs more
1738	resources and getting those fees to EPA instead of the
1739	Treasury is really important. I also appreciate, as you
1740	might imagine, that you have given the provision for small
1741	business reduced fees, and I wholeheartedly support that.
1742	So in general, just very much supportive of the bill and
1743	we think it fixes a lot of the problems with the current TSCA
1744	statute, and I am sure other issues will be raised but we
1745	look forward to working through them with you.
1746	[The prepared statement of Ms. Bosley follows:]

1748	Mr. {Shimkus.} Thank you very much.
1749	Now I would like to recognize Ms. Jennifer Thomas,
1750	Director of Federal Government Affairs with the Alliance of
1751	Automobile Manufacturers, again, another returnee. Welcome,
1752	and you have 5 minutes.

1753 ^STATEMENT OF JENNIFER THOMAS

1754 Ms. {Thomas.} Thank you, Chairman Shimkus, Ranking } 1755 Member Tonko. My name is Jennifer Thomas, and I am here on 1756 behalf of the Alliance of Automobile Manufacturers, which is 1757 a trade association of 12 automakers, and together they 1758 account for approximately 75 to 80 percent of all new vehicle 1759 sales here in the United States. The last time I was before 1760 this committee, I was beamed in from Europe, so I am very 1761 happy to be here in this person this time, so thank you for giving me the opportunity to share our views on the draft 1762 TSCA Modernization Act of 2015. 1763 1764 We commend Chairman Shimkus, Chairman Upton, and Ranking 1765 Member Pallone for their bipartisan efforts to reform TSCA for the first time since it was enacted in 1976. 1766 1767 Automakers work diligently to identify and reduce

1768 substances of concern in automobiles. We have eliminated the 1769 use of mercury switches and lead wheel weights. We continue 1770 to phase out the use of the flame retardant deca, and we are 1771 eliminating copper from brake pads.

1772 Autos are also one of the most recycled consumer 1773 products. Nearly 90 percent of a vehicle's material content 1774 is recycled or reused. 1775 But clearly there is more work to do to protect the public and environment from harmful chemical substances, and 1776 1777 we want to be part of the solution. We welcome this 1778 discussion draft and believe it will enhance EPA's ability to 1779 more effectively regulate potentially harmful chemicals while 1780 providing industry a clear and consistent regulatory 1781 environment.

Let me take a moment to highlight some specific areas of 1782 interest to our industry. First, we support the manner in 1783 1784 which this draft seeks to regulate chemicals and articles. 1785 This approach is consistent with existing EPA policy, which has traditionally recognized the complexity of regulating 1786 1787 chemicals and articles by exempting them from most TSCA 1788 requirements. We understand the potential need to regulate 1789 articles in certain circumstances but this should be based on 1790 risk of exposure to the chemical in question. For example, 1791 there is a clear difference between the risk of exposure to a chemical substance in a baby bottle versus an engine 1792

1793 component underneath the hood of a car.

1794 Secondly, we believe that vehicles should be serviced with parts as produced, meaning those service parts used the 1795 1796 material that were acceptable when the vehicle was designed, 1797 certified and warrantied. Replacement part demand is very 1798 small. It is generally 1 to 5 percent of all vehicle parts, 1799 and it declines over time as a vehicle fleet is retired. Btu 1800 since the average age of a vehicle on the road today is 11 1801 years, replacement parts must be available for many years so 1802 that those vehicles can be serviced and maintained.

1803 There is often some confusion of how vehicle replacement 1804 parts are produced, so let me briefly explain this model. 1805 Automakers typically put a marginal supply of those parts in 1806 stock while the vehicle is still in production, and to the 1807 extent that customers need replacement parts beyond that 1808 initial stock, there is a production-on-demand market, and 1809 suppliers continue to produce them using the same materials, 1810 the same production process, and the same engineering 1811 specifications as for the original vehicle. So while 1812 replacement parts might theoretically be able to be 1813 redesigned for vehicles no longer in production, there are

1814 technical and logistical barriers that often make such 1815 redesign infeasible if not impossible. 1816 I would also note that similar laws regulating chemical 1817 substances have examined this issue and have opted to exempt 1818 replacement parts. 1819 Finally, we appreciate this draft's simplified approach 1820 to state preemption, which ensures that any EPA final 1821 determination will preempt state chemical regulations. 1822 However, we do recommend that the committee also consider 1823 suspending any new state action while EPA decides a chemical 1824 substance is a candidate for a risk evaluation. We are aware 1825 of the concern expressed about the passage of time while EPA 1826 considers regulatory action and are supportive of expedited 1827 time frames for EPA action. 1828 Thank you again for inviting me to be here and discuss this important issue with you today. Congress is on the cusp 1829 1830 of reforming TSCA for the first time in nearly 40 years, and

1831 we strongly believe that the final bipartisan product will 1832 more effectively regulate harmful chemicals in a way that 1833 protects the health and safety of all Americans while 1834 providing industry the certainty and the clarity that it

1835	needs. We look forward to working with you as this draft
1836	moves through the legislative process.
1837	I thank you again, and I would be happy to answer any of
1838	your questions.
1839	[The prepared statement of Ms. Thomas follows:]

1841 Mr. {Shimkus.} Thank you very much.

1842 The chair now recognizes Mr. Andy Igrejas, Director of

1843 Safer Chemicals, Healthy Families. Welcome back. You are

1844 recognized for 5 minutes.

1845 STATEMENT OF ANDY IGREJAS 1846 Mr. {Igrejas.} Thank you very much, Mr. Chairman and } Mr. Tonko. I am pleased to be here as like the other 1847 1848 witnesses are. 1849 Safer Chemicals, Healthy Families is a coalition of 450 1850 organizations and businesses. It ranges from the Learning 1851 Disabilities Association, the Steelworkers Union, large 1852 health providers like Dignity Health, and the major national 1853 environmental organizations. We all came together to reform TSCA in 2009, and we 1854 1855 definitely want to have it happen sooner than later, and we 1856 are glad to work with the committee toward that end. 1857 I want to highlight what we see as positive in the draft, what is missing, and some ideas for how to move 1858 1859 forward. I want to also say up front that we think the more 1860 targeted approach you have taken does hold a lot of promise. 1861 There is a lot that it potentially solves and points the way 1862 forward, and also to identify some of the elements that are 1863 in there that we support.

1864 The absence of a complicated prioritization scheme we 1865 think is wise. It avoids the downside of the low-priority 1866 loophole that a lot of us are concerned about. You also 1867 heard from EPA that they already have prioritization criteria 1868 they have gone through that had public input, et cetera. 1869 The approach to preemption by preserving more of TSCA's 1870 existing preemption, you avoid the controversy of the void or 1871 the suspension whereby states are blocked just because EPA is 1872 looking at something, and we appreciate that. The draft also 1873 doesn't roll back EPA's authority on products or imports, so 1874 we think you have threaded the needle on the issue of products and don't take away authority on some of these other 1875 1876 areas. It doesn't make it easy to require toxicity testing. 1877 It does remove the least-burdensome requirement, which was an 1878 issue in the asbestos decision, and vulnerable populations 1879 are addressed though there is some clarification potentially 1880 needed around the rulemakings.

I want to focus on the issue of cost and see if I can add some value. It was talked about a lot. We basically agreed with where EPA came down on this, that we don't see that issue as solved in this draft, and to try to put it

1885 simply, I think in our vision, you want the risk evaluations 1886 to clearly identify the risk including the vulnerable 1887 populations and you want the rulemaking to have to protect 1888 against that risk very clearly. And then the cost 1889 considerations including cost-effectiveness comes into play 1890 with how EPA does that, which can mean longer time frames for 1891 implementing some particularly costly piece of the risk 1892 management. It can include choosing a more cost-effective 1893 way of addressing the risk over another way. But you don't 1894 want it to be a limitation on whether the risk is addressed 1895 at all, and that is the key distinction that we still see as 1896 potentially not solved. So it literally comes down to, will 1897 you have a risk hanging out there that EPA has identified and 1898 at the end we will be able to tell the story that the public 1899 is now protected from that risk and have that be true, or we potentially have the story that EPA winds up saying we 1900 1901 actually didn't protect against the risk because a court 1902 found that we couldn't prove that the cancer cases and the 1903 hospital visits, the lost work, et cetera, outweighed the 1904 costs to the companies to move to the safer alternative. 1905 That is the difference that this hinges on, and so I am not

1906 sure if we have a difference of intent or of interpretation 1907 of the language, but that is the key thing we would like to 1908 see solved is that the risk management has to protect against 1909 the risk.

1910 We also would agree with what has been said about the 1911 imbalance between industry assessments and the assessments 1912 that EPA would undertake under its own power under the draft. 1913 Really, the industry assessments are the only thing driving 1914 EPA activity under this draft. They have to agree to these 1915 requests and they have to undertake them, and on the flip 1916 side, they have to go through some hoops before they can 1917 undertake an assessment, and that creates an imbalance that 1918 we think could lead to them looking more at the chemicals 1919 that are already being managed well or that are already safe 1920 that have a lot of data instead of the ones that are causing 1921 problems out in the real world right now. And so we think if 1922 you got rid of those extra barriers put in place--this issue came up of 20 chemicals a year, a requirement perhaps to do 1923 1924 That is a nice round number. Maybe giving them a that. 1925 deadline to complete work on the chemicals that have been talked about, the 90 work plan chemicals, then we are on the 1926

1927 way to driving some EPA action on the chemicals in addition 1928 to having this industry-initiated assessments. 1929 We agree with what has been said about fees. I have 1930 mentioned some other issues in more detail in the written 1931 testimony around the science provisions in the bill. We 1932 think that you could take--if you are going with less is 1933 more, you can go all the way and not direct EPA to take a 1934 position on some of these scientific questions, but if you 1935 are going to do that, there are places in the bill where what 1936 you are calling for is stuff that the National Academy of 1937 Sciences has actually said EPA shouldn't do and there are 1938 some things the National Academies have said EPA should do that aren't in there, and so I would say pull back or go 1939 1940 further with what the National Academies would like to do. 1941 Persistent bioaccumulative toxins--these are the chemicals that are like PCBs. One of the only success 1942 1943 stories of the original TSCA, there is a limited number of them, chemicals that are like that, identifying them early 1944 1945 and requiring action.

1946 So I will stop there but I will just say that we think 1947 all the issues that we have identified are things that could

1948	be solved in the draft. We wouldn't support the draft in its
1949	current form. But with the changes that we have talked
1950	about, it could be getting in shape where you would have a
1951	genuine public health achievement here.
1952	[The prepared statement of Mr. Igrejas follows:]

1954 Mr. {Shimkus.} I thank you for your opening statement, 1955 and I will turn to myself for the start of the first round of 1956 questions and recognize myself for 5 minutes.

Mr. Walls, under section 6 of the House discussion draft, EPA must determine that a substance presents or will present in the absence of risk management measures and unreasonable risk of injury to health or the environment. Do

1961 you believe the discussion draft establishes a workable

1962 process for evaluating risk and identifying necessary risk

1963 management measures?

1964 Mr. {Walls.} Yes.

1965 Mr. {Shimkus.} Do you believe the discussion draft 1966 provides clear direction to EPA to consider only health and 1967 environment considerations in evaluating the risk of chemical 1968 substances?

1969 Mr. {Walls.} Yes.

1970 Mr. {Shimkus.} And then Dr. Bosley, do you agree with 1971 the bill's provision that breaks out risk evaluation, 1972 analysis of hazard and exposure as a separate question from 1973 the details of how to restrict a chemical by rulemaking?

1974 Ms. {Bosley.} Yes, I do.

1975 Mr. {Shimkus.} You have previously testified that 1976 Congress should include deadlines in TSCA. The updated 1977 discussion draft contains enforceable deadlines. Does the 1978 way that the discussion draft handles this matter satisfy 1979 you?

1980 Ms. {Bosley.} It does. I would like to see clearer 1981 deadlines that can be achieved by EPA.

1982 Mr. {Shimkus.} Are you concerned that deadlines might 1983 force EPA into making decisions to meet a deadline?

1984 Ms. {Bosley.} I am sorry. What was--

Mr. {Shimkus.} Do you think--well, the deadline issue, which is obviously a debatable question, would force them to make a quicker decision because of the deadline versus the science I guess is a better way to put it. Do you think the deadlines will force them to make bad--

1990 Ms. {Bosley.} A bad call?

1991 Mr. {Shimkus.} Yeah.

1992 Ms. {Bosley.} I don't think so. The scientists and 1993 engineers at the EPA are very talented, and I think given 1994 what we have seen with new chemicals, they are able to make

1995 decisions in a very timely manner, and I think with the

1996 correct resources for existing chemicals, I think it all

1997 hinges on that as to how quickly they can address, so with 1998 correct resources, they should be able to--

1999 Mr. {Shimkus.} What about the debate from the business 2000 perspective and the issue of litigation on missing a deadline 2001 or the like?

Ms. {Bosley.} Yeah. So I guess I would give--if it were me to write the bill, I would give EPA the ability to say look, this happened and so we need this much more time, we need another 3 months. So I would give them that ability. We wouldn't want that to go on for years and years but I would give them the ability to say well, there is this

2008 unforeseen circumstance and we need a little more time.

2009 Mr. {Shimkus.} The discussion draft permits a 2010 manufacturer to request EPA to conduct a risk evaluation of a 2011 chemical substance. Do you agree that this process can help

2012 EPA accelerate their review of existing chemicals in

2013 commerce?

2014 Ms. {Bosley.} I should think it would, yes.
2015 Mr. {Shimkus.} In your business, do you conduct a basic

2016 risk evaluation of your chemical products and could that 2017 information inform EPA's review of a substance? 2018 Ms. {Bosley.} We do. We don't do a reaction in the lab 2019 without performing a risk evaluation beforehand. 2020 Mr. {Shimkus.} So it kind of addresses some of the questions we had to Mr. Jones on definitive timelines, and I 2021 2022 quess to you and then I will go to Mr. Walls, talk about what 2023 would industry do if they are going to pay a fee to have a 2024 chemical reviewed? Would you think that there would be then 2025 a partnership that the sectors would be trying to work together or do you think they would just do that without 2026 providing information? 2027 2028 Ms. {Bosley.} Oh, no, I would think that they would 2029 work together. 2030 Mr. {Shimkus.} Because that would help you expedite the 2031 system. You could check your--2032 Ms. {Bosley.} In my case, for a small business, I would 2033 suspect we would have less to add than maybe a larger business, because I don't have any toxicologists on staff for 2034 2035 instance. So I would rely on EPA toxicologists. So it may differ between the actual business and the actual 2036

2037 circumstance how much information would be given but we would 2038 always try to participate very heavily with EPA. 2039 Mr. {Shimkus.} And Mr. Walls? 2040 Mr. {Walls.} Mr. Shimkus, I think what has been the 2041 hallmark of section 5 right now, the new chemical review 2042 provision, has been that it has promoted a dialog between the 2043 industry and EPA. I would see the same sort of circumstance 2044 applying here in the manufacturer-initiated process. 2045 Mr. {Shimkus.} And that again back to you, Mr. Walls 2046 and Dr. Bosley, and in this process under new chemicals, are 2047 you confident that confidential business information as you 2048 are going through this process with the EPA is currently 2049 being protected? Obviously that is a concern that we try to 2050 address a little bit. 2051 Mr. {Walls.} EPA has very rigorous controls to protect 2052 confidential information, yes. Ms. {Bosley.} I am confident all of our information is 2053 2054 protected. 2055 Mr. {Shimkus.} Great. I think that is all I have, so with that--and Mr. Igrejas, we look forward to continuing to 2056 work with you because obviously we are moving forward. There 2057

2058 is some bipartisan interest, and we want to continue to be

2059 open, so let's keep working together.

2060 With that, I yield back my time and turn to the ranking 2061 member, Mr. Tonko.

2062 Mr. {Tonko.} Thank you, Mr. Chair, and thank you again 2063 to all the members of the panel. Your testimony is obviously 2064 very helpful, and we appreciate your participation.

I would like to follow up on the earlier questions I had of the first panel member, and under the draft, manufacturers would have unlimited ability to require EPA to conduct risk evaluations, and there is no required number of EPA-initiated risk evaluations.

2070 Mr. Igrejas, do you find that to be a concern?

2071 Mr. {Igrejas.} We do. I would share the concern that 2072 Mr. Jones raised, that they really don't have the ability to-2073 -the discretion to turn down the request and then they have 2074 to complete it under an expedited time frame. I imagine that 2075 those risk evaluations would be valuable to a number of 2076 companies. There are a number of companies who have 2077 developed data and they would bring that forward. And even if that is all on the up and up, in other words, even if EPA 2078

2079 agrees and we would agree looking at the data, if that winds 2080 up being most of what they do, you are really not dealing 2081 with the chemicals that are causing a problem for public 2082 health and the environment right now. So even if you take the process at the most positive view of it--but I think 2083 2084 there is another element too which is as far as I can tell, 2085 the burden of proof would still be on EPA, so they have to 2086 undertake this evaluation but then the burden of proof is 2087 still on them if they find an unreasonable risk to prove with 2088 substantial evidence, et cetera, et cetera. So it is not 2089 that--they are not--they would be doing it a little bit under 2090 the gun in that sense. It is not like the drug burden of 2091 proof that we have.

2092 Mr. {Tonko.} And Mr. Jones spoke about the need for 2093 clarification to ensure that determinations as a risk must be 2094 acted on would not include cost considerations. Do you agree 2095 that EPA's determinations of whether a chemical substance 2096 needs risk management should be made without cost

2097 considerations?

2098 Mr. {Igrejas.} We would agree with what he said, that 2099 they should identify the risk cleanly, health only, is this

2100 causing an unreasonable amount of risk, cancer, learning 2101 disabilities, birth defects, et cetera, and then the rule 2102 should be required to adequately protect against the risk, 2103 and then the cost considerations should be sort of behind 2104 that line, how you do that, how quickly can we phase in 2105 alternatives, how quickly can we impose these restrictions. That is where the role of cost should come in. And the 2106 2107 draft, we would agree with him that it is a judgment call and 2108 we are concerned that a court could find that the old 2109 balancing still applies. As we know from the asbestos 2110 decision, that was where you had risks that were so severe, you had an unusual level of quantifiableness to the health 2111 cost of asbestosis and mesothelioma, and the court still find 2112 2113 that EPA couldn't prove that those quantifiable costs 2114 outweighed the benefits that asbestos brought to the economy. So it is a very--it is a big issue that has to be gotten 2115 2116 right.

2117 Mr. {Tonko.} So I am hearing a little clarification 2118 needed in the language of the draft.

2119 What about our other panelists in that regard to the 2120 cost language?

2121 Ms. {Bosley.} Oh, yeah, I think that clarification 2122 there to give EPA guidance would be very helpful. We 2123 wouldn't want it to end up in the courts as well. 2124 Mr. {Walls.} Mr. Tonko, I think the discussion draft 2125 reflects a desire to ensure that EPA continues to have the 2126 discretion, a considerable amount of discretion in managing 2127 the process, et cetera. I don't think that the language in 2128 and of itself mandates that EPA adopt a process that raises 2129 the very same problems we have under current law. I think 2130 the intent is clear to do something different if it takes an 2131 additional clarification to get there. I hesitate--2132 Mr. {Tonko.} If left as is, does it invite additional 2133 litigation? 2134 Mr. {Walls.} It might, but I think the clear intention 2135 here is that, you know, EPA ought to be taking a very 2136 reasonable approach in looking at what are the costs and 2137 efficiencies related to the regulatory options under 2138 discussion. 2139 Mr. {Tonko.} But I think we can agree that we all want 2140 to avoid any threat of additional litigation. 2141 Ms. Thomas?

2142 Ms. {Thomas.} I would agree with Mr. Walls, and just 2143 add that, you know, as an end user of chemicals, we strongly 2144 believe that cost should be a factor in the risk management 2145 process.

2146 Mr. {Tonko.} And if we could turn to the use of 2147 science, Mr. Igrejas, do you have concerns about the 2148 requirements to use the weight of the scientific evidence as 2149 defined in this draft?

2150 Mr. {Igrejas.} Yes, we do. Even though that phrase 2151 sounds innocuous, the National Academy of Sciences weighed in 2152 a report that Congress requested saying that the phrase was 2153 ambiguous and were concerned that it could cause some 2154 needless delays and potentially litigation hooks over what 2155 kind of information was included and referred to be EPA in an 2156 assessment.

2157 Mr. {Tonko.} Thank you. With that, I yield back, Mr.
2158 Chair.

2159 Mr. {Shimkus.} The gentleman's time is expired. The 2160 chair now recognizes the vice chair of the subcommittee, Mr. 2161 Harper, for 5 minutes.

2162 Mr. {Harper.} Thank you, Mr. Chairman, and thanks to

2163 each of you for being here.

2164 Ms. Thomas, if I may ask you a few questions, what is 2165 the typical lead time from, say, the design to the time that 2166 a new car is going to show up on the showroom floor? 2167 Ms. {Thomas.} Thank you for your question, and, you 2168 know, it varies amongst automakers but generally lead time is 2169 5 to 7 years for a new production model. It is obviously 2170 longer for advanced technologies like electric vehicles. But 2171 that goes back to the articles debate and why, if EPA were to 2172 take action on a chemical substance in an article there 2173 should be, you know, lead time should be considered in that 2174 process. 2175 Mr. {Harper.} So when EPA is looking at what they are

2175 Mr. {Harper.} So when EPA is looking at what they are 2176 going to do in a situation, that is something you believe 2177 they should take into account is that significant lead time 2178 on what they are going to try to do?

2179 Ms. {Thomas.} Absolutely, because we need that time to 2180 obviously make the necessary changes and suitable

2181 alternatives should also be available.

2182 Mr. {Harper.} What are some practical examples from 2183 your members that help illustrate why you are seeking these

2184 changes to TSCA?

2185 Ms. {Thomas.} So, you know, our top priority is one 2186 single national program for chemical management, and that it 2187 be implemented at the federal level. You know, a patchwork 2188 of inconsistent, conflicting state requirements just imposes 2189 a huge burden on complex durable-goods manufacturers like 2190 automakers. We manufacture vehicles to meet customer needs 2191 and to be sold in all 50 states, and inconsistent 2192 requirements, like, for example, there is--California and 2193 Washington State have brake friction standards to eliminate 2194 heavy metals and asbestos, and as much as they have tried to 2195 harmonize those regulations, there is still inconsistencies 2196 that we require a lot of resources and significant time 2197 obviously.

2198 Mr. {Harper.} So you can't have 50 different cars--the 2199 same car designed 50 different ways to sell in each state? 2200 Ms. {Thomas.} No, that would be quite challenging. 2201 Mr. {Harper.} Although sometimes you feel like that is 2202 what you might have to do.

2203 Please explain the technical, economic and logistical2204 barriers that often make such redesigned replacement parts

2205 infeasible if not perhaps impossible to achieve.

2206 Ms. {Thomas.} Sure. So like I indicated, there is a 2207 lot of confusion around this area. You know, we are not 2208 talking about all automobile parts, and we certainly don't 2209 believe that they should be exempt from TSCA requirements. 2210 We are talking about a small universe of parts, 1 to 5 2211 percent of vehicle production parts, and it is critical that 2212 those parts are needed to servicing and maintaining the 2213 existing fleet and, you know, the average age of a car is 11 2214 years old. We are making vehicles that last longer these 2215 days and so we have to be able to repair them and service 2216 them and so that is why that exemption is necessary. 2217 Mr. {Harper.} Thank you very much. 2218 Ms. Bosley, you have long been an advocate for 2219 maintaining section 5 and ensuring strong CBI protections.

2220 Does this updated discussion draft appropriately handle those 2221 sections to your satisfaction?

2222 Ms. {Bosley.} It does. We are very happy with 2223 maintaining the CBI with substantiation, and we are also 2224 happy to re-substantiate or not after a certain amount of 2225 years. Section 5 works very well. The deadlines are

2226	adequate, and EPA can always extend if they need it, so we
2227	are very happy with section 5.
2228	Mr. {Harper.} Do you believe that generic names and
2229	unique chemical qualifiers or identifiers will provide the
2230	public concrete enough information about your chemical
2231	without giving away your intellectual property?
2232	Ms. {Bosley.} I think so. I think that manufacturers
2233	work with EPA to provide robust generic chemical names that
2234	might identify the portion of the molecule that is causing
2235	the concern or the hazard, and that is where we need to get
2236	to.
2237	Mr. {Harper.} Thank you, and I yield back the balance
2238	of my time.
2239	Mr. {Shimkus.} The gentleman yields back his time. The
2240	chair recognizes the ranking member of the full committee,
2241	Mr. Pallone, for 5 minutes.
2242	Mr. {Pallone.} Thank you, Mr. Chairman.
2243	As I discussed with the first panel, I see some areas
2244	for improvement but I also think there are a lot of strong
2245	points in the chairman's discussion draft, so let me start
2246	with Mr. Igrejas.

I am particularly interested in your analysis that 2247 2248 leaving the unreasonable-risk language in place along with 2249 the heightened standard of judicial review could perpetuate 2250 the problems EPA has faced in regulating dangerous chemicals. 2251 So do you think an important measure of any TSCA reform 2252 proposal is whether it empowers EPA to regulate known 2253 dangerous chemicals like asbestos, for example? Mr. {Igrejas.} Certainly. I think that is the main 2254 2255 lesson from the asbestos decision. 2256 Mr. {Pallone.} Okay. Do you think it is important that any TSCA reform proposal provide for expedited action to 2257 2258 manage the risks from chemicals that are persistent, 2259 bioaccumulative and toxic? 2260 Mr. {Igrejas.} Absolutely. 2261 Mr. {Pallone.} And why is this expedited action important for those chemicals? 2262 2263 Mr. {Igrejas.} The lesson from TSCA's action on 2264 polychlorinated biphenyls, which is something TSCA originally 2265 did, is that those qualities taken together mean the chemical 2266 is around for a longer time and the risk winds up compounding because it builds up in the food chain. So the levels go up 2267

2268 for the end user, for people, over time and so you need to 2269 identify them earlier and take more aggressive action to 2270 restrict them earlier even to see the public health 2271 improvements 20 years later, and that is the story of PCBs. 2272 Mr. {Pallone.} Well, going back to PCBs, do you think 2273 that naming those chemicals in the statute helped move risk 2274 management forward, and would you support something similar 2275 for PBT chemicals?

2276 Mr. {Igrejas.} Well, we certainly would. We have 2277 supported that in the past. That is the simplest way of 2278 having them in the draft. You could also put in criteria for 2279 PBTs and require EPA to do the identification but naming this 2280 is fastest.

2281 Mr. {Pallone.} And I hope that we can work with the 2282 chairman as we move forward to include authorities for, you 2283 know, the way you suggested. I believe the draft shows the 2284 chairman's intent to ensure that the problems identified in 2285 Corrosion Proof Fittings are addressed, and that is an intent 2286 I share.

2287 I just wanted to, if I could, in the time I have left,2288 if I could just call attention to some of the strengths in

2289	this draft, which reflect points of strong agreement between
2290	stakeholders, and I just wanted to go down the line, you
2291	know, and as much as possible just answer yes or no, and I
2292	ask each of you to answer each of these questions.
2293	Do you support removing the least-burdensome language
2294	that has been an obstacle to EPA action under section 6? Mr.
2295	Walls?
2296	Mr. {Walls.} Yes.
2297	Mr. {Bosley.} Yes.
2298	Ms. {Thomas.} Yes.
2299	Mr. {Igrejas.} Yes.
2300	Mr. {Pallone.} Is the reporter able to get that? All
2301	right.
2302	Do you support giving EPA authority to require testing
2303	through orders, not just rulemaking? Mr. Walls?
2304	Mr. {Walls.} Yes.
2305	Mr. {Bosley.} Yes.
2306	Ms. {Thomas.} Yes.
2307	Mr. {Igrejas.} Yes.
2308	Mr. {Pallone.} Okay. I don't want to go too fast. Do
2309	you all support upfront substantiation of future CBI claims?

2310 Mr. {Walls.} Yes. 2311 Mr. {Bosley.} Yes. 2312 Ms. {Thomas.} Yes. Mr. {Igrejas.} Yes. 2313 2314 Mr. {Pallone.} Okay. Do you all support explicit protections for vulnerable populations? 2315 2316 Mr. {Walls.} Yes. I think the discussion draft 2317 appropriately acknowledges the need to address potentially 2318 exposed populations. 2319 Mr. {Pallone.} Dr. Bosley? 2320 Mr. {Bosley.} I do as well. 2321 Ms. {Thomas.} Yes, we do. 2322 Mr. {Igrejas.} Yes. 2323 Mr. {Pallone.} Okay. Do you all see these changes in 2324 the draft as valuable? Mr. {Walls.} Yes, although I wouldn't necessarily 2325 agree, Mr. Pallone, with Mr. Igrejas's comments regarding 2326 2327 asbestos and PBTs because the discussion draft limits in no 2328 way EPA's discretion to identify true priorities. But other 2329 than that, yes, we support changes. 2330 Mr. {Pallone.} Dr. Bosley?

2331 Mr. {Bosley.} We support as well.

2332 Mr. {Pallone.} Ms. Thomas?

2333 Ms. {Thomas.} We support as well.

2334 Mr. {Igrejas.} Yes.

2335 Mr. {Pallone.} Okay. And well, again, I got through 2336 this fairly quickly. I guess when you ask yes or no 2337 questions, it is easier to get through everything quickly. 2338 So I just want to again thank the chairman for working 2339 with us as we move forward to get this done. Thanks again.

2340 I yield back.

2341 Mr. {Shimkus.} The gentleman yields back his time. The 2342 chair now recognizes the gentleman from Oregon, Mr. Schrader, 2343 5 minutes.

2344 Mr. {Schrader.} I pass, Mr. Chairman.

2345 Mr. {Shimkus.} The gentleman passes, and the chair 2346 recognizes the gentleman from California, Mr. McNerney, for 5 2347 minutes.

2348 Mr. {McNerney.} Well, thank you, Mr. Chairman. I just 2349 want to say I appreciate your bipartisan work in getting this 2350 draft ready.

2351 Mr. {Shimkus.} Don't let that information out.

2352 Mr. {McNerney.} Okay. I will be careful not to. 2353 Mr. Igrejas, I am going to ask about the catch-22 2354 provision here. I don't think that has been asked yet. 2355 The ``may present unreasonable risk'', could you explain why that is a catch-22 and what we can do about that in the 2356 2357 draft? 2358 Mr. {Igrejas.} Sure. I think the lesson of TSCA, and 2359 because of the approach in this draft, I think it got a lot 2360 of us looking back at original TSCA more, and you read it, 2361 and there are a lot of things that sound reasonable, they sound like they should have worked, and it just turned out 2362 2363 that when a court got into them and EPA anticipating that, they didn't. They really turned out to be significant 2364 2365 barriers to EPA acting, and I think this would be in this category. On its face, it sounds like before EPA should get 2366 started, shouldn't they decided well, this might be something 2367 that is a problem, but the history I think of this statute 2368 2369 and of EPA interpreting is that it could trip them up

2370 substantially. If they really have to show that it may 2371 before they undertake the evaluation to see if it does, it

2372 seems unnecessary in the spirit of the more striped-down 2373 approach in expediting them taking action. 2374 Mr. {McNerney.} Okay. Now, the heightened standard of 2375 judicial review, EPA actions taken under TSCA must be 2376 supported by substantial evidence in the rulemaking record, 2377 and that is a substantially higher--well, that is significantly higher than the ``arbitrary and capricious'' 2378 2379 standard that is normally used for EPA rules. Could you 2380 comment on how that could be improved in the TSCA? 2381 Mr. {Igrejas.} We think taking it out would be the improvement in having ``arbitrary and capricious'' apply to 2382 2383 this statute as well. One of the things I think is lost is, 2384 it is not just that the court threw out the EPA rulemaking on 2385 asbestos but that because of substantial evidence, it took 2386 EPA 10 years to put together that record. I think it was a 40,000-page record. And so it has an impact on how much 2387 2388 time--how much EPA feels it has to put under its feet in 2389 order to go forth and make a rulemaking in addition to the 2390 risk of something getting thrown out of court. So I feel it 2391 being removed would put it in line with other environmental 2392 laws.

2393 Mr. {McNerney.} Well, my understanding is, the 2394 ``supported by substantial evidence in the rulemaking 2395 record'' is what prevented the rules on asbestos from being 2396 implemented. 2397 Mr. {Igrejas.} That is right. 2398 Mr. {McNerney.} And that is clearly, you know, a 2399 disadvantage. 2400 Mr. {Igrejas.} It was the third leg of the stool, so to 2401 speak, in preventing EPA from taking action on asbestos. 2402 Mr. {McNerney.} Okay. Thank you, Mr. Chairman. I yield back. 2403 Mr. {Shimkus.} The gentleman yields back his time. 2404 2405 Seeing no other members present, I want to thank the panel for coming. It was a pretty good hearing. I think 2406 2407 there are things that we want to continue to discuss. I did 2408 announce a date for a subcommittee mark, and the only thing I 2409 will say too is, as we move forward, we don't have to get it 2410 prefect right the first bite. We have subcommittee, we have 2411 full committee. Then hopefully the Senate will move 2412 something. We go to conference. There is going to be a lot of opportunities. But I appreciate the positive comments 2413

2414 from all my colleagues. I understand the issues that they 2415 have concerns on. We look forward to really having an opportunity to get this thing done, and we look for your 2416 2417 input to be able to do that. 2418 So I will dismiss the second panel, and I will ask unanimous consent that all members of the subcommittee have 5 2419 2420 legislative days to submit opening statements for the record. 2421 I also ask unanimous consent that the following letters 2422 to the subcommittee regarding the discussion draft at our 2423 hearing today be included in the record. The letters are 2424 from the American Cleaning Institute, the Environmental 2425 Working Group, the Bipartisan Policy Center, Society of 2426 Toxicologists, the American Alliance for Justice, and a statement by Dr. Paul Lock. Without objection, so ordered. 2427 2428 [The information follows:]

2430 Mr. {Shimkus.} And I will adjourn the hearing. 2431 [Whereupon, at 12:15 p.m., the Subcommittee was 2432 adjourned.]